References
References
Abilify (aripiprazole) [product monograph]. Saint-Laurent, QC, Canada, Otsuka Canada Pharmaceutical, November 2017
Abilify (aripiprazole) [prescribing information]. Rockville, MD, Otsuka America Pharmaceutical, August 2019
Abilify Maintena (aripiprazole) [prescribing information]. Rockville, MD, Otsuka America Pharmaceutical, March 2018. Available at: www.otsuka-us.com/media/static/Abilify-M-PI.pdf. Accessed January 20, 2019.
Abilify Mycite (aripiprazole) [prescribing information]. Rockville, MD, Otsuka America Pharmaceutical, November 2017
Acevedo A, Garnick DW, Dunigan R, et al: Performance measures and racial/ethnic disparities in the treatment of substance use disorders. J Stud Alcohol Drugs 76(1):57–67, 2015
Achtyes E, Simmons A, Skabeev A, et al: Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. BMC Psychiatry 18(1):292, 2018 30223804
ACOG Committee on Practice Bulletins—Obstetrics: ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 111(4):1001–1020, 2008 18378767
Acosta FJ, Hernández JL, Pereira J, et al: Medication adherence in schizophrenia. World J Psychiatry 2(5):74–82, 2012 24175171
Addington D, McKenzie E, Smith H, et al: Conformance to evidence-based treatment recommendations in schizophrenia treatment services. Can J Psychiatry 57(5):317–323, 2012 22546064
Addington DE, Norman R, Bond GR, et al: Development and testing of the First-Episode Psychosis Services Fidelity Scale. Psychiatr Serv 67(9):1023–1025, 2016 27032665
Addington D, Abidi S, Garcia-Ortega I, et al: Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders. Can J Psychiatry 62(9):594–603, 2017a
Addington D, Anderson E, Kelly M, et al: Canadian practice guidelines for comprehensive community treatment for schizophrenia and schizophrenia spectrum disorders. Can J Psychiatry 62(9):662–672, 2017b
Addington D, Birchwood M, Jones P, et al: Fidelity scales and performance measures to support implementation and quality assurance for first episode psychosis services. Early Interv Psychiatry 12(6):1235–1242, 2018 29882236
Addington J, Addington D, Abidi S, et al: Canadian treatment guidelines for individuals at clinical high risk of psychosis. Can J Psychiatry 62(9):656–661, 2017 28730848
Adelufosi AO, Abayomi O, Ojo TM: Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev April 13(4):CD010501, 2015 25866243
Agency for Healthcare Research and Quality: Methods guide for effectiveness and comparative effectiveness reviews (AHRQ Publ No 10(14)-EHC063-EF). Rockville, MD, Agency for Healthcare Research and Quality, January 2014. Available at: www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318. Accessed February 15, 2017.
Agerwala SM, McCance-Katz EF: Integrating screening, brief intervention, and referral to treatment (SBIRT) into clinical practice settings: a brief review. J Psychoactive Drugs 44(4):307–317, 2012 23210379
Aggarwal NK, Lewis-Fernández R: An introduction to the Cultural Formulation Interview. Focus 13(4):426–431, 2015
Ahalt C, Williams B: Reforming solitary-confinement policy: heeding a presidential call to action. N Engl J Med 374(18):1704–1706, 2016 27144846
Ahalt C, Haney C, Rios S, et al: Reducing the use and impact of solitary confinement in corrections. Int J Prison Health 13(1):41–48, 2017 28299967
Ahmed S, Khan AM, Mekala HM, et al: Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: a comparative meta-analysis. Heliyon 3(11):e00429, 2017 29264404
Ajmal A, Joffe H, Nachtigall LB: Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics 55(1):29–36, 2014 24140188
Alabed S, Latifeh Y, Mohammad HA, Bergman H: Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev Apr 17 4(4):CD000203, 2018 29663328
Alastal Y, Hasan S, Chowdhury MA, et al: Hypertriglyceridemia-induced pancreatitis in psychiatric patients: a case report and review of literature. Am J Ther 23(3):e947–949, 2016 24987947
Alban RF, Nuño M, Ko A, et al: Weaker gun state laws are associated with higher rates of suicide secondary to firearms. J Surg Res 221:135–142, 2018 29229119
Alberti KG, Eckel RH, Grundy SM, et al: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645, 2009 19805654
Aleman A, Enriquez-Geppert S, Knegtering H, Dlabac-de Lange JJ: Moderate effects of noninvasive brain stimulation of the frontal cortex for improving negative symptoms in schizophrenia: meta-analysis of controlled trials. Neurosci Biobehav Rev 89:111–118, 2018 29471017
Ali SA, Mathur N, Malhotra AK, Braga RJ: Electroconvulsive therapy and schizophrenia: a systematic review. Mol Neuropsychiatry 5(2):75–83, 2019 31192220
Alldredge BK: Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 53(5 suppl 2):S68–S75, 1999 10496236
Allen JG, Frueh BC, Ellis TE, et al: Integrating outcomes assessment and research into clinical care in inpatient adult psychiatric treatment. Bull Menninger Clin 73(4):259–295, 2009
Almerie MQ, Al Marhi MO, Jawoosh M, et al: Social skills programmes for schizophrenia. Cochrane Database Syst Rev Jun 9(6):CD009006, 2015 26059249
Al-Rousan T, Rubenstein L, Sieleni B, et al: Inside the nation’s largest mental health institution: a prevalence study in a state prison system. BMC Public Health 17(1):342, 2017 28427371
Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, et al: Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 22(7):547–562, 2008 18547125
Alvir JM, Lieberman JA, Safferman AZ, et al: Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 329(3):162–167, 1993 8515788
Amantadine hydrochloride capsules [prescribing information]. High Point, NC, Banner Life Sciences, December 2015
Amantadine hydrochloride oral solution [prescribing information]. Farmville, NC, CMP Pharma, January 2015
Amantadine hydrochloride tablets [prescribing information]. Yardley, PA, Vensun Pharmaceuticals, January 2019
American Academy of Pediatrics and the American College of Obstetricians and Gynecologists: Guidelines for Perinatal Care, 8th Edition. Elk Grove Village, IL, American Academy of Pediatrics; Washington, DC, American College of Obstetricians and Gynecologists, 2017
American College of Correctional Physicians: Restricted housing of mentally ill inmates. Marion, MA, American College of Correctional Physicians, 2013. Available at: http://accpmed.org/restricted_housing_of_ mentally.php. Accessed September 22, 2019.
American College of Obstetricians and Gynecologists: ACOG Committee Opinion No. 736: Optimizing postpartum care. Obstet Gynecol 131(5):e140–e150, 2018 29683911
American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice; Breastfeeding Expert Work Group: Committee Opinion No. 658: Optimizing support for breastfeeding as part of obstetric practice. Obstet Gynecol 127(2):e86–92, 2016 26942393
American Diabetes Association: 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care 41 (suppl 1):S13–S27, 2018
American Geriatrics Society Expert Panel on Person-Centered Care: Person-centered care: a definition and essential elements. J Am Geriatr Soc 64(1):15–18, 2016 26626262
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000
American Psychiatric Association: Practice Guideline for the Treatment of Patients With Schizophrenia, 2nd Edition. Arlington, VA, American Psychiatric Publishing, 2004
American Psychiatric Association: Position statement on treatment of substance use disorders in the criminal justice system. Arlington, VA, American Psychiatric Association, 2007. Available at: www.psychiatry.org/File%20Library/About-APA/Organization-Documents-Policies/Policies/Position-2007-Substance-Abuse-Criminal-Justice.pdf. Accessed September 22, 2019.
American Psychiatric Association: Guideline Watch: Practice Guideline for the Treatment of Patients With Schizophrenia. Arlington, VA, American Psychiatric Publishing, 2009a
American Psychiatric Association: Position statement on atypical antipsychotic medications. Arlington, VA, American Psychiatric Association, 2009b. Available at: www.psychiatry.org/File%20Library/About-APA/Organization-Documents-Policies/Policies/Position-2009-Atypical-Antipsychotics.pdf. Accessed September 22, 2019.
American Psychiatric Association: Outpatient services for the mentally ill involved in the criminal justice system. Arlington, VA, American Psychiatric Association, 2009c. Available at: www.psychiatry.org/File%20 Library/Psychiatrists/Directories/Library-and-Archive/task-force-reports/tfr2009_outpatient.pdf. Accessed September 27, 2019.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA, American Psychiatric Association, 2013a
American Psychiatric Association: Clinician-rated dimensions of psychosis symptom severity, in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA, American Psychiatric Association, 2013b, pp 743–744. Available at: www.psychiatry.org/File%20Library/Psychiatrists/Practice/DSM/APA_DSM5_ Clinician-Rated-Dimensions-of-Psychosis-Symptom-Severity.pdf. Accessed November 10, 2019.
American Psychiatric Association: DSM-5 self-rated level 1 cross-cutting symptom measure—adult, in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA, American Psychiatric Association, 2013c, pp 738–739. Available at: www.psychiatry.org/File%20Library/Psychiatrists/Practice/DSM/APA_DSM5_Level-1-Measure-Adult.pdf. Accessed November 10, 2019.
American Psychiatric Association: WHODAS 2.0 (World Health Organization Disability Assessment Schedule 2.0): 36-item version, self-administered, in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA, American Psychiatric Association, 2013d, pp 747–748. Available at: www.psychiatry.org/ psychiatrists/practice/dsm/educational-resources/assessment-measures. Accessed November 10, 2019.
American Psychiatric Association: Glossary of technical terms, in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA, American Psychiatric Association, 2013e, pp 817–831
American Psychiatric Association: The Principles of Medical Ethics With Annotations Especially Applicable to Psychiatry, 2013 Edition. Arlington, VA, American Psychiatric Association, 2013f. Available at: www.psychiatry.org/File%20Library/Psychiatrists/Practice/Ethics/principles-medical-ethics.pdf. Accessed November 18, 2018.
American Psychiatric Association: Resource document on involuntary outpatient commitment and related programs of assisted outpatient treatment. Arlington, VA, American Psychiatric Association, 2015. Available at: www.psychiatry.org/psychiatrists/search-directories-databases/library-and-archive/resource-documents. Accessed October 2, 2019.
American Psychiatric Association: Practice Guidelines for the Psychiatric Evaluation of Adults, 3rd Edition. Arlington, VA, American Psychiatric Association Publishing, 2016a
American Psychiatric Association: Psychiatric Services in Correctional Facilities, 3rd Edition. Arlington, VA, American Psychiatric Association Publishing, 2016b
American Psychiatric Association: Position statement on segregation of prisoners with mental illness. Arlington, VA, American Psychiatric Association, 2017. Available at: www.psychiatry.org/File%20Library/About-APA/Organization-Documents-Policies/Policies/Position-2012-Prisoners-Segregation.pdf. Accessed September 22, 2019.
American Psychiatric Association: Position statement on solitary confinement (restricted housing) of juveniles. Washington, DC, American Psychiatric Association, 2018. Available at: www.psychiatry.org/File%20Library/About-APA/Organization-Documents-Policies/Policies/Position-2018-Solitary- Confinement-Restricted-Housing-of-Juveniles.pdf. Accessed October 3, 2019.
American Public Health Association: Solitary confinement as a public health issue. Washington, DC, American Public Health Association, 2013. Available at: www.apha.org/policies-and-advocacy/public-health-policy-statements/policy-database/2014/07/14/13/30/solitary-confinement-as-a-public-health-issue. Accessed on September 22, 2019.
Ananth J, Sangani H, Noonan JP: Amantadine in drug-induced extrapyramidal signs: a comparative study. Int J Clin Pharmacol Biopharm 11(4):323–326, 1975 239908
Anderson GD, Chan LN: Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet 55(11):1353–1368, 2016
Anderson KE, Stamler D, Davis MD, et al: Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 4(8):595–604, 2017 28668671
Anderson KK, Norman R, MacDougall A, et al: Effectiveness of early psychosis intervention: comparison of service users and nonusers in population-based health administrative data. Am J Psychiatry 175(5):443–452, 2018 29495897
Andorn A, Graham J, Csernansky J, et al: Monthly extended-release risperidone (RBP-7000) in the treatment of schizophrenia: results from the phase 3 program. J Clin Psychopharmacol 39(5):428–433, 2019 31343440
Andreasen NC: Scale for the Assessment of Negative Symptoms. Iowa City, University of Iowa, 1984a
Andreasen NC: Scale for the Assessment of Positive Symptoms. Iowa City, University of Iowa, 1984b
Andrews JC, Schünemann HJ, Oxman AD, et al: GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength. J Clin Epidemiol 66(7):726–735, 2013 23570745
Anestis MD, Houtsma C: The association between gun ownership and statewide overall suicide rates. Suicide Life Threat Behav 48(2):204–217, 2018 28294383
Ang MS, Abdul Rashid NA, Lam M, et al: The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia. J Clin Psychopharmacol 37(6):651–656, 2017 29016375
Angell B, Matthews E, Barrenger S, et al: Engagement processes in model programs for community reentry from prison for people with serious mental illness. Int J Law Psychiatry 37(5):490–500, 2014 24650496
Angus S, Sugars J, Boltezar R, et al: A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 17(2):88–91, 1997 10950469
Appelbaum PS: Clinical practice: assessment of patients’ competence to consent to treatment. N Engl J Med 357(18):1834–1840, 2007
Appelbaum PS, Le Melle S: Techniques used by assertive community treatment (ACT) teams to encourage adherence: patient and staff perceptions. Community Ment Health J 44(6):459–464, 2008 18516679
Arana GW, Goff DC, Baldessarini RJ, Keepers GA: Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 145(8):993–996, 1988 2899403
Aripiprazole orally disintegrating tablets [prescribing information]. Bridgewater, NJ, Alembic Pharmaceuticals, November 2018
Aripiprazole solution [prescribing information]. Weston, FL, Apotex, November 2016
Aristada (aripiprazole lauroxil) [prescribing information]. Waltham, MA, Alkermes, August 2019
Aristada Initio (aripiprazole lauroxil) [prescribing information]. Waltham, MA, Alkermes, August 2019
Ascher-Svanum H, Zhu B, Faries D, et al: A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 67(7):1114–1123, 2006 16889456
Aune D, Sen A, Norat T, et al: Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation 133(7):639–649, 2016 26746176
Austedo (deutetrabenazine) tablets [prescribing information]. North Wales, PA, Teva Pharmaceuticals USA, July 2019
Aytemir K, Maarouf N, Gallagher MM, et al: Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms. Pacing Clin Electrophysiol 22(9):1397–1401, 1999 10527023
Bachmann CJ, Aagaard L, Bernardo M, et al: International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand 136(1):37–51, 2017 28502099
Bai YM, Ting Chen T, Chen JY, et al: Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 68(8):1218–1225, 2007 17854246
Baillargeon J, Binswanger IA, Penn JV, et al: Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry 166(1):103–109, 2009a 19047321
Baillargeon J, Penn JV, Thomas CR, et al: Psychiatric disorders and suicide in the nation’s largest state prison system. J Am Acad Psychiatry Law 37(2):188–193, 2009b 19535556
Baillargeon J, Hoge SK, Penn JV: Addressing the challenge of community reentry among released inmates with serious mental illness. Am J Community Psychol 46(3–4):361–375, 2010 20865315
Bak M, Fransen A, Janssen J, et al: Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 9(4):e94112, 2014 24763306
Balon R, Berchou R: Hematologic side effects of psychotropic drugs. Psychosomatics 27(2):119–120, 125–127, 1986 2869545
Balshem H, Helfand M, Schünemann HJ, et al: GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401–406, 2011 21208779
Barber S, Olotu U, Corsi M, Cipriani A: Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev (3):CD006324, 2017 28333365
Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology: Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 25(5):567–620, 2011
Barnhill JW: The psychiatric interview and mental status examination, in The American Psychiatric Publishing Textbook of Psychiatry, 6th Edition. Edited by Hales RE, Yudofsky SC, Roberts LW. Arlington, VA, American Psychiatric Association, 2014, pp 3–30
Barrowclough C, Tarrier N, Lewis S, et al: Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia. Br J Psychiatry 174:505–511, 1999 10616628
Bartels SJ, Pratt SI, Mueser KT, et al: Long-term outcomes of a randomized trial of integrated skills training and preventive healthcare for older adults with serious mental illness. Am J Geriatr Psychiatry 22(11):1251–1261, 2014 23954039
Bartels SJ, Pratt SI, Aschbrenner KA, et al: Pragmatic replication trial of health promotion coaching for obesity in serious mental illness and maintenance of outcomes. Am J Psychiatry 172(4):344–352, 2015 25827032
Bassett AS, Chow EW: 22q11 deletion syndrome: a genetic subtype of schizophrenia. Biol Psychiatry 46(7):882–891, 1999 10509171
Bassett AS, Lowther C, Merico D, et al: International 22q11.2DS Brain and Behavior Consortium: rare genome-wide copy number variation and expression of schizophrenia in 22q11.2 deletion syndrome. Am J Psychiatry 174(11):1054–1063, 2017 28750581
Bäuml J, Froböse T, Kraemer S, et al: Psychoeducation: a basic psychotherapeutic intervention for patients with schizophrenia and their families. Schizophr Bull 32 (suppl 1):S1–S9, 2006 16920788
Bebbington P, Jakobowitz S, McKenzie N, et al: Assessing needs for psychiatric treatment in prisoners, 1: prevalence of disorder. Soc Psychiatry Psychiatr Epidemiol 52(2):221–229, 2017 27878322
Bech P, Austin SF, Timmerby N, et al: A clinimetric analysis of a BPRS-6 scale for schizophrenia severity. Acta Neuropsychiatr 30(4):187–191, 2018 29409548
Beck AT, Rector NA: Cognitive approaches to schizophrenia: theory and therapy. Annu Rev Clin Psychol 1:577–606, 2005 17716100
Beck AT, Rector NA, Stolar N, Grant P: Schizophrenia: Cognitive Theory, Research, and Therapy. New York, Guilford, 2009, p 418
Beck Institute: CBT for schizophrenia. Bala Cynwyd, PA, Beck Institute, 2019. Available at: https://beckinstitute.org/workshop/cbt-for-schizophrenia. Accessed May 6, 2020.
Becker DR, Drake RE: A Working Life for People With Severe Mental Illness. New York, Oxford University Press, 2003
Bellack AS, Goldberg RW: VA Psychosocial Rehabilitation Training Program: social skills training for serious mental illness. Baltimore, MD, MIRECC VISN 5, 2019. Available at: www.mirecc.va.gov/visn5/training/sst/sst_clinicians_handbook.pdf. Accessed April 11, 2019.
Bellack AS, Mueser KT, Gingerich S, Agresta J: Social Skills Training for Schizophrenia: A Step-by-Step Guide, 2nd Edition. New York, Guilford, 2004
Bellissima BL, Tingle MD, Cicović A, et al: A systematic review of clozapine-induced myocarditis. Int J Cardiol 259:122–129, 2018
Bellou V, Belbasis L, Tzoulaki I, Evangelou E: Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses. PLoS One 13(3):e0194127, 2018
Benadryl (diphenhydramine) [prescribing information]. Fort Washington, PA, McNeil Consumer Healthcare, June 2018
Benztropine injection [prescribing information]. Lake Forest, IL, Akorn, November 2017
Benztropine tablets [prescribing information]. Livonia, MI, Major Pharmaceuticals, October 2017
Bergamo C, Sigel K, Mhango G, et al: Inequalities in lung cancer care of elderly patients with schizophrenia: an observational cohort study. Psychosom Med 76(3):215–220, 2014
Bergman H, Soares-Weiser K: Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev Jan 17 1(1):CD000204, 2018
Bergman H, Walker DM, Nikolakopoulou A, et al: Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess 21(43):1–218, 2017
Bergman H, Bhoopathi PS, Soares-Weiser K: Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev Jan 20 1(1):CD000205, 2018a
Bergman H, Rathbone J, Agarwal V, Soares-Weiser K: Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev Feb 6 2(2):CD000459, 2018b
Berman BD: Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist 1(1):41–47, 2011
Bertelsen M, Jeppesen P, Petersen L, et al: Suicidal behaviour and mortality in first-episode psychosis: the OPUS trial. Br J Psychiatry Suppl 51:s140–s146, 2007
Bertilsson L: Metabolism of antidepressant and neuroleptic drugs by cytochrome P450s: clinical and interethnic aspects. Clin Pharmacol Ther 82(5):606–609, 2007
Bhidayasiri R, Fahn S, Weiner WJ, et al; American Academy of Neurology: Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 81(5):463–469, 2013
Bird AM, Smith TL, Walton AE: Current treatment strategies for clozapine-induced sialorrhea. Ann Pharmacother 45(5):667–675, 2011
Bishara D, Olofinjana O, Sparshatt A, et al: Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol 33(3):329–335, 2013
Bitter I, Katona L, Zámbori J, et al: Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Eur Neuropsychopharmacol 23(11):1383–1390, 2013
Blanchet PJ, Abdillahi O, Beauvais C, et al: Prevalence of spontaneous oral dyskinesia in the elderly: a reappraisal. Mov Disord 19(8):892–896, 2004
Bliss SA, Warnock JK: Psychiatric medications: adverse cutaneous drug reactions. Clin Dermatol 31(1):101–109, 2013
Bolton JM, Morin SN, Majumdar SR, et al: Association of mental disorders and related medication use with risk for major osteoporotic fractures. JAMA Psychiatry 74(6):641–648, 2017
Bonfioli E, Berti L, Goss C, et al: Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry 12:78, 2012
Bonoldi I, Simeone E, Rocchetti M, et al: Prevalence of self-reported childhood abuse in psychosis: a meta-analysis of retrospective studies. Psychiatry Res 210(1):8–15, 2013
Borison RL: Amantadine in the management of extrapyramidal side effects. Clin Neuropharmacol 6 (suppl 1): S57–S63, 1983
Bouchama A, Dehbi M, Mohamed G, et al: Prognostic factors in heat wave related deaths: a meta-analysis. Arch Intern Med 167(20):2170–2176, 2007
Bousman CA, Dunlop BW: Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J 18(5):613–622, 2018
Bouwmans C, de Sonneville C, Mulder CL, Hakkaart-van Roijen L: Employment and the associated impact on quality of life in people diagnosed with schizophrenia. Neuropsychiatr Dis Treat 11:2125–2142, 2015
Bower T, Samek DA, Mohammed A, et al: Systemic medication usage in glaucoma patients. Can J Ophthalmol 53(3):242–245, 2018
Bowie CR, Reichenberg A, Patterson TL, et al: Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 163(3):418–425, 2006
Bowtell M, Eaton S, Thien K, et al: Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. Schizophr Res 195:231–236, 2018
Bradley-Engen MS, Cuddeback GS, Gayman MD, et al: Trends in state prison admission of offenders with serious mental illness. Psychiatr Serv 61(12):1263–1265, 2010
Braham LG, Trower P, Birchwood M: Acting on command hallucinations and dangerous behavior: a critique of the major findings in the last decade. Clin Psychol Rev 24(5):513–528, 2004
Brain C, Kymes S, DiBenedetti DB, et al: Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study. BMC Psychiatry 18(1):253, 2018 30103719
Brand RM, McEnery C, Rossell S, et al: Do trauma-focussed psychological interventions have an effect on psychotic symptoms? A systematic review and meta-analysis. Schizophr Res 195:13–22, 2018 28844432
Brashear A, Ambrosius WT, Eckert GJ, Siemers ER: Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 13(1):158-161, 1998 9452343
Briggs GG, Freeman RK, Towers CV, Forinash AB: Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 11th Edition. Philadelphia, PA, Wolters Kluwer, 2017
Brito JP, Domecq JP, Murad MH, et al: The Endocrine Society guidelines: when the confidence cart goes before the evidence horse. J Clin Endocrinol Metab 98(8):3246–3252, 2013 23783104
Bromet EJ, Kotov R, Fochtmann LJ, et al: Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry 168(11):1186–1194, 2011
Bromet EJ, Nock MK, Saha S, et al; World Health Organization World Mental Health Survey Collaborators: Association between psychotic experiences and subsequent suicidal thoughts and behaviors: a cross-national analysis from the World Health Organization World Mental Health Surveys. JAMA Psychiatry 74(11):1136–1144, 2017 28854302
Brown JD, Barrett A, Caffery E, et al: State and demographic variation in use of depot antipsychotics by Medicaid beneficiaries with schizophrenia. Psychiatr Serv 65(1):121–124, 2014 24382765
Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry 177:212–217, 2000
Browne J, Penn DL, Bauer DJ, et al: Perceived autonomy support in the NIMH RAISE Early Treatment Program. Psychiatr Serv 68(9):916–922, 2017 28566027
Brunette MF, Mueser KT, Babbin S, et al: Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophr Res 194:4–12, 2018 28697856
Bruno V, Valiente-Gómez A, Alcoverro O: Clozapine and fever: a case of continued therapy with clozapine. Clin Neuropharmacol 38(4):151–153, 2015 26166236
Buchanan A, Sint K, Swanson J, Rosenheck R: Correlates of future violence in people being treated for schizophrenia. Am J Psychiatry 176(9):694–701, 2019 Epub ahead of print
Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71–93, 2010
Buckley L A, Maayan N, Soares-Weiser K, Adams CE: Supportive therapy for schizophrenia. Cochrane Database Syst Rev (4):CD004716, 2015 2587146
Buckley PF, Schooler NR, Goff DC, et al: Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull 41(2):449–459, 2015 24870446
Buckley PF, Schooler NR, Goff DC, et al: Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study. Psychiatr Serv 67(12):1370–1372, 2016 27476806
Buhagiar K, Jabbar F: Association of first- vs. second-generation antipsychotics with lipid abnormalities in individuals with severe mental illness: a systematic review and meta-analysis. Clin Drug Investig 39(3):253–273, 2019 30675684
Burke RE, Fahn S, Jankovic J, et al: Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 32(12):1335–1346, 1982 6128697
Burnett AL, Bivalacqua TJ: Priapism: new concepts in medical and surgical management. Urol Clin North Am 38(2):185–194, 2011 21621085
Burns AM, Erickson DH, Brenner CA: Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review. Psychiatr Serv 65(7):874–880, 2014 24686725
Burns T, Catty J, Becker T, et al; EQOLISE Group: The effectiveness of supported employment for people with severe mental illness: a randomised controlled trial. Lancet 370(9593):1146–1152, 2007 17905167
Burns T, Rugkåsa J, Molodynski A, et al: Community treatment orders for patients with psychosis (OCTET): a randomised controlled trial. Lancet 381(9878):1627–1633, 2013
Bush G, Fink M, Petrides G, et al: Catatonia I: rating scale and standardized examination. Acta Psychiatr Scand 93(2):129–136, 1996a
Bush G, Fink M, Petrides G, et al: Catatonia II: treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand 93(2):137–143, 1996b 8686484
Bushe C, Paton C: The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? J Psychopharmacol 19(6 suppl):76–83, 2005 16280340
Caemmerer J, Correll CU, Maayan L: Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 140(1–3):159–168, 2012 22763424
Carbon M, Hsieh CH, Kane JM, Correll CU: Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry 78(3):e264–e278, 2017 28146614
Carbon M, Kane JM, Leucht S, Correll CU: Tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 17(3):330–340, 2018 30192088
Carney R, Cotter J, Firth J, et al: Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta-analysis. Acta Psychiatr Scand 136(1):5–15, 2017
Caroff SN, Mann SC: Neuroleptic malignant syndrome. Psychopharmacol Bull 24(1):25–29, 1988 3290944
Caroff SN, Mann SC, Keck PE Jr, Francis A: Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 20(2):257–259, 2000 10770467
Caroli F, Raymondet P, Izard I, et al: Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence 5:165–171, 2011 21573047
Carrillo JA, Herraiz AG, Ramos SI, Benítez J: Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol 18(4):311–316, 1998 9690697
Carruthers J, Radigan M, Erlich MD, et al: An initiative to improve clozapine prescribing in New York State. Psychiatr Serv 67(4):369–371, 2016 26725299
Cassidy RM, Yang F, Kapczinski F, Passos IC: Risk factors for suicidality in patients with schizophrenia: a systematic review, meta-analysis, and meta-regression of 96 studies. Schizophr Bull 44(4):787–797, 2018 29036388
Castelein S, Bruggeman R, Davidson L, van der Gaag M: Creating a supportive environment: peer support groups for psychotic disorders. Schizophr Bull 41(6):1211–1213, 2015 26297694.
Catley D, Goggin K, Harris KJ, et al: A randomized trial of motivational interviewing: cessation induction among smokers with low desire to quit. Am J Prev Med 50(5):573–583, 2016 26711164
Cella M, Preti A, Edwards C, et al: Cognitive remediation for negative symptoms of schizophrenia: a network meta-analysis. Clin Psychol Rev 52:43–51, 2017 27930934
Cella M, Wykes T: The nuts and bolts of cognitive remediation: exploring how different training components relate to cognitive and functional gains. Schizophr Res 203:12–16, 2019 28919130
Center for Evidence-Based Practices: Assertive community treatment. Cleveland, OH, Case Western Reserve University, 2019. Available at: www.centerforebp.case.edu/practices/act. Accessed March 31, 2019.
Center for Health Policy/Center for Primary Care and Outcomes Research and Battelle Memorial Institute: Quality Indicator Measure Development, Implementation, Maintenance, and Retirement. Contract No 290-04-0020. Rockville, MD, Agency for Healthcare Research and Quality, May 2011. Available at: www.qualityindicators.ahrq.gov/Downloads/Resources/Publications/2011/QI_Measure_Development_ Implementation_Maintenance_Retirement_Full_5-3-11.pdf. Accessed April 2, 2017.
Center for Substance Abuse Treatment: Trauma-Informed Care in Behavioral Health Services. Treatment Improvement Protocol (TIP) Series No 57. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2014. Available at: www.ncbi.nlm.nih.gov/books/NBK207201. Accessed May 10, 2019.
Centers for Disease Control and Prevention: Infection Control Basics: Standard Precautions for All Patient Care. Atlanta, GA, Centers for Disease Control and Prevention, January 26, 2016. Available at: www.cdc.gov/infectioncontrol/basics/standard-precautions.html. Accessed October 4, 2019.
Centers for Disease Control and Prevention: FAQs Regarding Safe Practices for Medical Injections. Atlanta, GA, Centers for Disease Control and Prevention, June 20, 2019a. Available at: www.cdc.gov/injectionsafety/providers/provider_faqs.html. Accessed July 22, 2020.
Centers for Disease Control and Prevention: Vaccine Recommendations and Guidelines of the ACIP: Vaccine Administration. Atlanta, GA, Centers for Disease Control and Prevention, June 21, 2019b. Available at: www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html. Accessed October 4, 2019.
Centers for Disease Control and Prevention: Tobacco Use and Quitting Among Individuals With Behavioral Health Conditions. Atlanta, GA, Centers for Disease Control and Prevention, 2020. Available at: www.cdc.gov/tobacco/disparities/mental-illness-substance-use/index.htm. Accessed July 8, 2020.
Cerovecki A, Musil R, Klimke A, et al: Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 27(7):545–572, 2013 23821039
Challis S, Nielssen O, Harris A, Large M: Systematic meta-analysis of the risk factors for deliberate self-harm before and after treatment for first-episode psychosis. Acta Psychiatr Scand 127(6):442–454, 2013
Chapel JM, Ritchey MD, Zhang D, Wang G: Prevalence and medical costs of chronic diseases among adult Medicaid beneficiaries. Am J Prev Med 53(6S2):S143–S154, 2017 29153115
Charzyńska K, Kucharska K, Mortimer A: Does employment promote the process of recovery from schizophrenia? A review of the existing evidence. Int J Occup Med Environ Health 28(3):407–418, 2015 26190722
Chasser Y, Kim AY, Freudenreich O: Hepatitis C treatment: clinical issues for psychiatrists in the post-interferon era. Psychosomatics 58(1):1–10, 2017
Chatziralli IP, Sergentanis TN: Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology 118(4):730–735, 2011 21168223
Chen SY, Ravindran G, Zhang Q, et al: Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis. CNS Drugs 33(3):225–238, 2019 30758782
Chien WT, Clifton AV, Zhao S, Lui S: Peer support for people with schizophrenia or other serious mental illness. Cochrane Database Syst Rev April 4 4(4):CD010880, 2019 30946482
Chisolm MS, Payne JL: Management of psychotropic drugs during pregnancy. BMJ 532:h5918, 2016 26791406
Chlorpromazine hydrochloride injection [prescribing information]. Deerfield, IL, Baxter, September 2010
Chlorpromazine hydrochloride injection [prescribing information]. Eatontown, NJ, West-Ward Pharmaceuticals, November 2016
Chlorpromazine hydrochloride tablets [prescribing information]. Bridgewater, NJ, Amneal Pharmaceuticals, January 2018
Cho J, Hayes RD, Jewell A, et al: Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta Psychiatr Scand 139(3):237–247, 2019
Chouinard G, Jones B, Remington G, et al: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13(1):25–40, 1993
Cimo A, Stergiopoulos E, Cheng C, et al: Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: a systematic review. BMC Psychiatry 12:24, 2012 22443212
Citrome L: Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol 37(2):138–147, 2017a 28141623
Citrome L: Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication—What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 71(7), 2017b
Citrome L, Volavka J, Czobor P, et al: Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 52(11):1510–1514, 2001
Claghorn J, Honigfeld G, Abuzzahab FS Sr, et al: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7(6):377–384, 1987 3323261
Clarke DE, Wilcox HC, Miller L, et al: Feasibility and acceptability of the DSM-5 Field Trial procedures in the Johns Hopkins Community Psychiatry Programs. Int J Methods Psychiatr Res 23(2):267–278, 2014 24615761
Clausen W, Watanabe-Galloway S, Baerentzen MB, Britigan DH: Health literacy among people with serious mental illness. Community Ment Health J 52(4):399–405, 2016
Clayton AH, McGarvey EL, Clavet GJ: The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 33(4):731–745, 1997a 9493486
Clayton AH, McGarvey EL, Clavet GJ, Piazza L: Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 33(4):747–753, 1997b 9493487
Cloud DH, Drucker E, Browne A, Parsons J: Public health and solitary confinement in the United States. Am J Public Health 105(1):18–26, 2015 25393185
Cloutier M, Aigbogun MS, Guerin A, et al: The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry 77(6):764–771, 2016 27135986
Clozapine [prescribing information]. Greenville, NC, Mayne Pharma, June 2017
Clozapine REMS Program: Recommended monitoring frequency and clinical decisions by ANC level. Phoenix, AZ, Clozapine REMS Program, December 23, 2014. Available at: www.clozapinerems.com/CpmgClozapineUI/ rems/pdf/resources/ANC_Table.pdf. Accessed February 12, 2019.
Clozapine REMS Program: Prescriber certification. Phoenix, AZ, Clozapine REMS Program, 2019a. Available at: www.clozapinerems.com/CpmgClozapineUI/hcpHome.u. Accessed February 12, 2019.
Clozapine REMS Program: Program materials: prescriber. Phoenix, AZ, Clozapine REMS Program, 2019b. Available at: www.clozapinerems.com/CpmgClozapineUI/resources.u#tabr4. Accessed February 12, 2019.
Clozapine REMS Program: Clozapine and the risk of neutropenia: a guide for healthcare providers. Phoenix, AX, Clozpine REMS Program, February 2019c. Available at: www.clozapinerems.com/CpmgClozapineUI/ rems/pdf/resources/Clozapine_REMS_A_Guide_for_Healthcare_Providers.pdf. Accessed July 14, 2020.
Clozaril (clozapine) [prescribing information]. East Hanover, NJ, Novartis Pharmaceuticals, January 2017
Clozaril (clozapine) [product monograph]. Etobicoke, ON, Canada, HLS Therapeutics, July 2019
Cogentin (benztropine) injection [prescribing information]. Lake Forest, IL, Akorn, May 2013
Cohen AN, Drapalski AL, Glynn SM, et al: Preferences for family involvement in care among consumers with serious mental illness. Psychiatr Serv 64(3):257–263, 2013 23242515
Cohen AN, Hamilton AB, Saks ER, et al: How occupationally high-achieving individuals with a diagnosis of schizophrenia manage their symptoms. Psychiatr Serv 68(4):324–329, 2017 27842472
Coid JW, Ullrich S, Kallis C, et al: The relationship between delusions and violence: findings from the East London first episode psychosis study. JAMA Psychiatry 70(5):465–471, 2013 23467760
College of Psychiatric and Neurologic Pharmacists: Psychiatric pharmacy essentials: antipsychotic dose equivalents. Lincoln, NE, College of Psychiatric and Neurologic Pharmacists, 2019. Available at: https://cpnp.org/guideline/essentials/antipsychotic-dose-equivalents. Accessed February 25, 2019.
Conley RR, Kelly DL, Richardson CM, et al: The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol 23(6):668–671, 2003 14624201
Conus P, Cotton S, Schimmelmann BG, et al: Rates and predictors of 18-months remission in an epidemiological cohort of 661 patients with first-episode psychosis. Soc Psychiatry Psychiatr Epidemiol 52(9):1089–1099, 2017 28477070
Cook BL, Wayne GF, Kafali EN, et al: Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA 311(2):172–182, 2014 24399556
Cook JA, Leff HS, Blyler CR, et al: Results of a multisite randomized trial of supported employment interventions for individuals with severe mental illness. Arch Gen Psychiatry 62(5):505–512, 2005 15867103
Cookson J, Hodgson R, Wildgust HJ: Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol 26(5 suppl):42–51, 2012 22472310
Copeland ME: Wellness recovery action plan. Occup Ther Ment Health 17:(3–4), 127–150, 2000
Correll CU, Robinson DG, Schooler NR, et al: Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry 71(12):1350–1363, 2014 25321337
Correll CU, Citrome L, Haddad PM, et al: The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry 77 (suppl 3):1–24, 2016 27732772
Correll CU, Josiassen RC, Liang GS, et al: Efficacy of valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and mood disorder. Psychopharmacol Bull 47(3):53–60, 2017a 28839340
Correll CU, Rubio JM, Inczedy-Farkas G, et al: Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 74(7):675–684, 2017b 28514486
Correll CU, Solmi M, Veronese N, et al: Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 16(2):163–180, 2017c
Correll CU, Rubio JM, Kane JM: What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 17(2):149–160, 2018
Cotton SM, Filia KM, Ratheesh A, et al: Early psychosis research at Orygen, the National Centre of Excellence in Youth Mental Health. Soc Psychiatry Psychiatr Epidemiol 51(1):1–13, 2016 26498752
Couchman L, Morgan PE, Spencer EP, Flanagan RJ: Plasma clozapine, norclozapine, and the clozapine: norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993–2007. Ther Drug Monit 32(4):438–447, 2010 20463634
Coulter C, Baker KK, Margolis RL: Specialized consultation for suspected recent-onset schizophrenia: diagnostic clarity and the distorting impact of anxiety and reported auditory hallucinations. J Psychiatr Pract 25(2):76–81, 2019 30849055
Council of Medical Specialty Societies: Principles for the Development of Specialty Society Clinical Guidelines. Chicago, IL, Council of Medical Specialty Societies, 2012
Craig TK, Garety P, Power P, et al: The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ 329(7474):1067, 2004 15485934
Credible Meds: Risk categories for drugs that prolong QT and induce torsades de pointes (TdP). Oro Valley, AZ, Credible Meds, 2019. Available at: https://crediblemeds.org/healthcare-providers/drug-list. Accessed May 6, 2020.
Creed TA, Stirman SW, Evans AC, Beck AT: A model for implementation of cognitive therapy in community mental health: the Beck Initiative. Behav Ther 37(3):56–64, 2014
Crockford D, Addington D: Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders. Can J Psychiatry 62(9):624–634, 2017
Crosby AE, Ortega L, Melanson C: Self-Directed Violence Surveillance: Uniform Definitions and Recommended Data Elements, Version 1.0. Atlanta, GA, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, February 2011. Available at: www.cdc.gov/violenceprevention/pdf/self-directed-violence-a.pdf. Accessed May 25, 2015.
Crow TJ, Cross AJ, Johnstone EC, et al: Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J Clin Psychopharmacol 2(5):336–340, 1982 7130435
Cunqueiro A, Durango A, Fein DM, et al: Diagnostic yield of head CT in pediatric emergency department patients with acute psychosis or hallucinations. Pediatr Radiol 49(2):240–244, 2019 30291381
Czobor P, Van Dorn RA, Citrome L, et al: Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol 25(8):1158–1166, 2015 26004980
D’Amato T, Bation R, Cochet A, et al: A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Schizophr Res 125(2–3):284–290, 2011 21094025
Daod E, Krivoy A, Shoval G, et al: Psychiatrists’ attitude towards the use of clozapine in the treatment of refractory schizophrenia: a nationwide survey. Psychiatry Res 275:155–161, 2019 30913436
Das C, Mendez G, Jagasia S, Labbate LA: Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry 24(3):225–239, 2012 22860242
Dauwan M, Begemann MJ, Heringa SM, Sommer IE: Exercise improves clinical symptoms, quality of life, global functioning, and depression in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 42(3):588–599, 2016 26547223
Davidson M: The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia. Dialogues Clin Neurosci 20(3):215–221, 2018 30581291
Davis JM, Chen N: Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 24(2):192–208, 2004 15206667
de Boer MK, Castelein S, Wiersma D, et al: A systematic review of instruments to measure sexual functioning in patients using antipsychotics. J Sex Res 51(4):383–389, 2014 24754359
de Boer MK, Castelein S, Wiersma D, et al: The facts about sexual (dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull 41(3):674–686, 2015 25721311
De Hert M, Correll CU, Bobes J, et al: Physical illness in patients with severe mental disorders, I: prevalence, impact of medications and disparities in health care. World Psychiatry 10(1):52–77, 2011 21379357
De Hert M, Peuskens J, Sabbe T, et al: Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand 133(1):5–22, 2016 26114737
Delahunty A, Morice R: Rehabilitation of frontal/executive impairments in schizophrenia. Aust N Z J Psychiatry 30(6):760–767, 1996 9034464
de Leon J, Diaz FJ: A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 76(2–3):135–157, 2005
Depression and Bipolar Support Alliance: Restoring intimacy. Chicago, IL, Depression and Bipolar Support Alliance, 2019. Available at: www.dbsalliance.org/education/related-concerns/sexual-health-and-mood-disorders/restoring-intimacy. Accessed May 6, 2019.
de Oliveira IR, de Sena EP, Pereira EL, et al: Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis. J Clin Pharm Ther 21(4):229–236, 1996 8933296
de Silva VA, Suraweera C, Ratnatunga SS, et al: Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry 16(1):341, 2016 27716110
Desmarais JE, Beauclair L, Margolese HC: Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol 26(9):1167–1174, 2012 22651987
Deste G, Barlati S, Cacciani P, et al: Persistence of effectiveness of cognitive remediation interventions in schizophrenia: a 1-year follow-up study. Schizophr Res 161(2–3):403–406, 2015 25533593
DeTore NR, Hintz K, Khare C, Mueser KT: Disclosure of mental illness to prospective employers: Clinical, psychosocial, and work correlates in persons receiving supported employment. Psychiatry Res 273:312–317, 2019 30677720
Devinsky O, Pacia SV: Seizures during clozapine therapy. J Clin Psychiatry 55 (suppl B):153–156, 1994 7961562
Devinsky O, Honigfeld G, Patin J: Clozapine-related seizures. Neurology 41(3):369–371, 1991 2006003
de Vries B, van Busschbach JT, van der Stouwe ECD, et al: Prevalence rate and risk factors of victimization in adult patients with a psychotic disorder: a systematic review and meta-analysis. Schizophr Bull 45(1):114–126, 2019 29547958
Dewa CS, Loong D, Trojanowski L, Bonato S: The effectiveness of augmented versus standard individual placement and support programs in terms of employment: a systematic literature review. J Ment Health 27(2):174–183, 2018 28488948
de With SAJ, Pulit SL, Staal WG, et al: More than 25 years of genetic studies of clozapine-induced agranulocytosis. Pharmacogenomics J 17(4):304–311, 2017 28418011
Dickenson R, Momcilovic S, Donnelly L: Anticholinergics vs placebo for neuroleptic-induced parkinsonism. Schizophr Bull 43(1):17, 2017 27585460
Dickerson F, Schroeder J, Katsafanas E, et al: Cigarette smoking by patients with serious mental illness, 1999–2016: an increasing disparity. Psychiatr Serv 69(2):147–153, 2018 28945183
Diener E, Emmons RA, Larsen RJ, Griffin S: The Satisfaction With Life Scale. J Pers Assess 49(1):71–75, 1985 16367493
DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE: A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 33(5):599–602, 1976 5066
Diphenhydramine hydrochloride injection [prescribing information]. Lake Forest, IL, Hospira, May 2019
Dixon LB, Dickerson F, Bellack AS, et al; Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 36(1):48–70, 2010 19955389
Dixon LB, Lucksted A, Medoff DR, et al: Outcomes of a randomized study of a peer-taught Family-to-Family Education Program for mental illness. Psychiatr Serv 62(6):591–597, 2011 21632725
Dixon LB, Holoshitz Y, Nossel I: Treatment engagement of individuals experiencing mental illness: review and update. World Psychiatry 15(1):13–20, 2016 26833597
Djulbegovic B, Trikalinos TA, Roback J, et al: Impact of quality of evidence on the strength of recommendations: an empirical study. BMC Health Serv Res 9:120, 2009 19622148
Dold M, Li C, Tardy M, et al: Benzodiazepines for schizophrenia. Cochrane Database Syst Rev Nov 14 11(11):CD006391, 2012 23152236
Dold M, Li C, Gillies D, Leucht S: Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 23(9):1023–1033, 2013 23602690
Dold M, Fugger G, Aigner M, et al: Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Res 166(1–3):187–193, 2015 26008883
Dollfus S, Lecardeur L, Morello R, Etard O: Placebo response in repetitive transcranial magnetic stimulation trials of treatment of auditory hallucinations in schizophrenia: a meta-analysis. Schizophr Bull 42(2):301–308, 2016 26089351
Dondé C, Vignaud P, Poulet E, et al: Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines. Acta Psychiatr Scand 138(4):289–299, 2018 29974451
Donnelly K, Bracchi R, Hewitt J, et al: Benzodiazepines, Z-drugs and the risk of hip fracture: a systematic review and meta-analysis. PloS One 12(4):e0174730, 2017 28448593
Donoghue K, Doody GA, Murray RM, et al: Cannabis use, gender and age of onset of schizophrenia: data from the ÆSOP study. Psychiatry Res 215(3):528–532, 2014 24461684
Donohoe G, Dillon R, Hargreaves A, et al: Effectiveness of a low support, remotely accessible, cognitive remediation training programme for chronic psychosis: cognitive, functional and cortical outcomes from a single blind randomised controlled trial. Psychol Med 48(5):751–764, 2018 28933314
Dougall N, Maayan N, Soares-Weiser K, et al: Transcranial magnetic stimulation (TMS) for schizophrenia. Cochrane Database Syst Rev Aug 20(8):CD006081, 2015 26289586
Draine J, Blank Wilson A, Metraux S, et al: The impact of mental illness status on the length of jail detention and the legal mechanism of jail release. Psychiatr Serv 61(5):458–462, 2010 20439365
Drake R, Skinner J, Goldman HH: What explains the diffusion of treatments for mental illness? Am J Psychiatry 165(11):1385–1392, 2008
Drake RE, Gates C, Whitaker A, Cotton PG: Suicide among schizophrenics: a review. Compr Psychiatry 26(1):90–100, 1985
Drapalski AL, Piscitelli S, Lee RJ, et al: Family involvement in the clinical care of clients with first-episode psychosis in the RAISE Connection Program. Psychiatr Serv 69(3):358–361, 2018 29089013
Druss BG, Bradford DW, Rosenheck RA, et al: Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 283(4):506–511, 2000 10659877
Druss BG, Zhao L, von Esenwein SA, et al: The Health and Recovery Peer (HARP) Program: a peer-led intervention to improve medical self-management for persons with serious mental illness. Schizophr Res 118(1–3):264–270, 2010 20185272
Druss BG, Chwastiak L, Kern J, et al: Psychiatry’s role in improving the physical health of patients with serious mental illness: a report from the American Psychiatric Association. Psychiatr Serv 69(3):254–256, 2018 29385957
Durbin J, Selick A, Langill G, et al: Using fidelity measurement to assess quality of early psychosis intervention services in Ontario. Psychiatr Serv 70(9):840–844, 2019 31159664
Dyck DG, Short RA, Hendryx MS, et al: Management of negative symptoms among patients with schizophrenia attending multiple-family groups. Psychiatr Serv 51(4):513–519, 2000 10737828
Dzahini O, Singh N, Taylor D, Haddad PM: Antipsychotic drug use and pneumonia: systematic review and meta-analysis. J Psychopharmacol 32(11):1167–1181, 2018 30334664
Easter MM, Swanson JW, Robertson AG, et al: Facilitation of psychiatric advance directives by peers and clinicians on assertive community treatment teams. Psychiatr Serv 68(7):717–723, 2017 28366114
Ekström J, Godoy T, Riva A: Clozapine: agonistic and antagonistic salivary secretory actions. J Dent Res 89(3):276–280, 2010 20093673
Ellison JC, Dufresne RL: A review of the clinical utility of serum clozapine and norclozapine levels. Ment Health Clin 5(2):68–73, 2015
El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H: Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev (1):CD000458, 2018 29342497
Essali A, Rihawi A, Altujjar M, et al: Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. Cochrane Database Syst Rev Dec 19(12):CD009546, 2013 24353163
Essock S, Addington D: Coordinated Specialty Care for People With First Episode Psychosis: Assessing Fidelity to the Model. Alexandria, VA, National Association of State Mental Health Program Directors, 2018. Available at: www.nasmhpd.org/sites/default/files/Issue_Brief_Fidelity.pdf. Accessed October 9, 2019.
Essock SM, Covell NH, Davis SM, et al: Effectiveness of switching antipsychotic medications. Am J Psychiatry 163(12):2090–2095, 2006 17151159
Eum S, Lee AM, Bishop JR: Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci 18(3):323–337, 2016 27757066
Every-Palmer S, Ellis PM: Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal ‘slow gut’ reactions, and comparison with international drug safety advice. CNS Drugs 31(8):699–709, 2017 28623627
Factor SA, Remington G, Comella CL, et al: The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry 78(9):1344–1350, 2017 29141124
Fagiolini A, Rocca P, De Giorgi S, et al: Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: randomized controlled trials vs naturalistic studies. Psychiatry Res 247:257–264, 2017 27936437
Falkenberg I, Benetti S, Raffin M, et al: Clinical utility of magnetic resonance imaging in first-episode psychosis. Br J Psychiatry 211(4):231–237, 2017 28473319
Fanapt (iloperidone) [prescribing information]. Washington, DC, Vanda Pharmaceuticals, February 2017
Fann WE, Lake CR: Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 133(8):940–943, 1976 782262
Farooq S, Choudry A, Cohen D, et al: Barriers to using clozapine in treatment-resistant schizophrenia: systematic review. BJPsych Bull 43(1):8–16, 2019 30261942
Farreny A, Aguado J, Ochoa S, et al: REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res 142(1–3):137–144, 2012 23017827
FazaClo (clozapine) [prescribing information]. Palo Alto, CA, Jazz Pharmaceuticals, February 2017
Fazel S, Gulati G, Linsell L, et al: Schizophrenia and violence: systematic review and meta-analysis. PLoS Med 6(8):e1000120, 2009a 19668362
Fazel S, Långström N, Hjern A, et al: Schizophrenia, substance abuse, and violent crime. JAMA 301(19):2016–2023, 2009b
Fazel S, Wolf A, Palm C, Lichtenstein P: Violent crime, suicide, and premature mortality in patients with schizophrenia and related disorders: a 38-year total population study in Sweden. Lancet Psychiatry 1(1):44–54, 2014 25110636
Fenton WS: Evolving perspectives on individual psychotherapy for schizophrenia. Schizophr Bull 26(1):47–72, 2000 10755669
Fenton WS, Blyler CR, Wyatt RJ, McGlashan TH: Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry 171:265–268, 1997 9337982
Fernandes-Taylor S, Harris AH: Comparing alternative specifications of quality measures: access to pharmacotherapy for alcohol use disorders. J Subst Abuse Treat 42(1):102–107, 2012
Fernandez HH, Factor SA, Hauser RA, et al: Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology 88(21):2003–2010, 2017 28446646
Ferrando SJ, Owen JA, Levenson JL: Psychopharmacology, in The American Psychiatric Publishing Textbook of Psychiatry, 6th Edition. Edited by Hales RE, Yudofsky SC, Roberts LW. Washington, DC, American Psychiatric Publishing, 2014, pp 929–1003
Fink M: Rediscovering catatonia: the biography of a treatable syndrome. Acta Psychiatr Scand Suppl 441:1–47, 2013 23215963
Firth J, Cotter J, Elliott R, et al: A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med 45(7):1343–1361, 2015 25650668
Firth J, Stubbs B, Rosenbaum S, et al: Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis. Schizophr Bull 43(3):546–556, 2017 27521348
Firth J, Siddiqi N, Koyanagi A, et al: The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 6(8):675–712, 2019 31324560
Fleischhacker WW, Kane JM, Geier J et al: Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial. J Clin Psychiatry 75(3):e184–190, 2014 24717389
Fluphenazine decanoate injection [prescribing information]. Chestnut Ridge, NY, Par Pharmaceutical, April 2018
Fluphenazine hydrochloride elixir [prescribing information]. Greenville, SC, Pharmaceutical Associates, December 2016
Fluphenazine hydrochloride injection [prescribing information]. Schaumburg, IL, APP Pharmaceuticals, September 2010
Fluphenazine hydrochloride solution, concentrate [prescribing information]. Greenville, SC, PAI, August 2010
Fluphenazine hydrochloride tablets [prescribing information]. Morgantown, WV, Mylan, November 2016
Foglia E, Schoeler T, Klamerus E, et al: Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. Psychol Med 47(10):1691–1705, 2017 28179039
Fond G, Berna F, Boyer L, et al; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group: Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. Eur Arch Psychiatry Clin Neurosci 268(1):17–26, 2018 28349247
Fontanella CA, Campo JV, Phillips GS, et al: Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. J Clin Psychiatry 77(5):661–667, 2016 27249075
Forbes M, Stefler D, Velakoulis D, et al: The clinical utility of structural neuroimaging in first-episode psychosis: a systematic review. Aust N Z J Psychiatry 53(11):1093–1104, 2019 Epub ahead of print
Fortney JC, Unützer J, Wrenn G, et al: A tipping point for measurement-based care. Psychiatr Serv 68(2):179–188, 2017
Frank JD, Frank JB: Persuasion and Healing: A Comparative Study of Psychotherapy, 3rd Edition. Baltimore, MD, Johns Hopkins University Press, 1991
Frederick DE, VanderWeele TJ: Supported employment: meta-analysis and review of randomized controlled trials of individual placement and support. PLoS One 14(2):e0212208, 2019 30785954
Frei K, Truong DD, Fahn S, et al: The nosology of tardive syndromes. J Neurol Sci 389:10–16, 2018 29433810
Freudenreich O, Francis A, Fricchione GL: Psychosis, mania, and catatonia, in The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psychiatry, 3rd Edition. Edited by Levenson JL. Washington, DC, American Psychiatric Association Publishing, 2019, pp 249–279
Fries BE, Schmorrow A, Lang SW, et al: Symptoms and treatment of mental illness among prisoners: a study of Michigan state prisons. Int J Law Psychiatry 36(3–4):316–325, 2013 23688801
Froes Brandao D, Strasser-Weippl K, Goss PE: Prolactin and breast cancer: the need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: a review. Cancer 122(2):184–188, 2016 26457577
Fung WL, Butcher NJ, Costain G, et al: Practical guidelines for managing adults with 22q11.2 deletion syndrome. Genet Med 17(8):599–609, 2015 25569435
Funk MC, Beach SR, Bostwick JR, et al: Resource document on QTc prolongation and psychotropic medications. APA Resource Document. Washington, DC, American Psychiatric Association, 2018. Available at: www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/resource_ documents/Resource-Document-2018-QTc-Prolongation-and-Psychotropic-Med.pdf. Accessed December 7, 2018.
Fusar-Poli P, Cappucciati M, Borgwardt S, et al: Heterogeneity of psychosis risk within individuals at clinical high risk: a meta-analytical stratification. JAMA Psychiatry 73(2):113–120, 2016 26719911
Gabbard GO: Techniques of psychodynamic psychotherapy, in Textbook of Psychotherapeutic Treatments. Edited by Gabbard GO. Washington, DC, American Psychiatric Publishing, 2009, pp 43–67
Gaebel W, Riesbeck M, von Wilmsdorff M, et al; EUFEST Study Group: Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol 20(5):310–316, 2010 20202800
Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al: Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 19(1):69–76, 2017 27388693
Gaedigk A, Ingelman-Sundberg M, Miller NA, et al; PharmVar Steering Committee:Tthe Pharmacogene Variation (PharmVar) Consortium: incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. Clin Pharmacol Ther 103(3):399–401, 2018 29134625
Galletly C, Castle D, Dark F, et al: Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 50(5):410–472, 2016
Galling B, Roldán A, Hagi K, et al: Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 16(1):77–89, 2017 28127934
Ganesh M, Jabbar U, Iskander FH: Acute laryngeal dystonia with novel antipsychotics: a case report and review of literature. J Clin Psychopharmacol 35(5):613–615, 2015 26252439
Gao K, Fang F, Wang Z, Calabrese JR: Subjective versus objective weight gain during acute treatment with second-generation antipsychotics in schizophrenia and bipolar disorder. J Clin Psychopharmacol 36(6):637–642, 2016 27753728
García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al: Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 36(4):355–371, 2016 27307187
Garety PA, Fowler DG, Freeman D, et al: Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. Br J Psychiatry 192(6):412–423, 2008 18515890
Gaynes BN, Brown C, Lux LJ, et al: Management Strategies to Reduce Psychiatric Readmissions (Technical Brief No 21, AHRQ Publ No 15-EHC018-EF). Rockville, MD, Agency for Healthcare Research and Quality, May 2015. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed October 3, 2019.
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1789–1858, 2018 30496104
Gee SH, Shergill SS, Taylor DM: Patient attitudes to clozapine initiation. Int Clin Psychopharmacol 32(6):337–342, 2017 28704228
Geodon (ziprasidone) [prescribing information]. New York, Pfizer, November 2018
Gertner AK, Grabert B, Domino ME, et al: The effect of referral to expedited Medicaid on substance use treatment utilization among people with serious mental illness released from prison. J Subst Abuse Treat 99:9–15, 2019 30797401
Ghany MG, Hoofnagle JH: Approach to the patient with liver disease, in Harrison’s Principles of Internal Medicine, 20th Edition. Edited by Jameson J, Fauci AS, Kasper DL, et al. New York, McGraw-Hill, 2018. Available at: https://accessmedicine.mhmedical.com/content.aspx?bookid=2129§ionid=192283281. Accessed May 6, 2020.
Gibson LM, Paul L, Chappell FM, et al: Potentially serious incidental findings on brain and body magnetic resonance imaging of apparently asymptomatic adults: systematic review and meta-analysis. BMJ 363:k4577, 2018 30467245
Gierisch JM, Nieuwsma JA, Bradford DW, et al: Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry 75(5):e424–e440, 2014 24922495
Glowa-Kollisch S, Kaba F, Waters A, et al: From punishment to treatment: the “Clinical Alternative to Punitive Segregation” (CAPS) program in New York City jails. Int J Environ Res Public Health 13(2):182, 2016 26848667
Glynn SM, Marder SR, Liberman RP, et al: Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry 159(5):829–837, 2002 11986138
Glynn SM, Cather C, Gingerich S, et al: NAVIGATE Family Education Program, April 1, 2014. Available at: http://www.navigateconsultants.org/wp-content/uploads/2017/05/FE-Manual.pdf. Accessed October 9, 2019.
Godwin-Austen RB, Clark T: Persistent phenothiazine dyskinesia treated with tetrabenazine. Br Med J 4(5778):25–26, 1971 4938245
Goff DC, Arana GW, Greenblatt DJ, et al: The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 11(2):106–112, 1991 2056136
Goff DC, Falkai P, Fleischhacker WW, et al: The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry 74(9):840–849, 2017 28472900
Goldberg RW, Dickerson F, Lucksted A, et al: Living Well: an intervention to improve self-management of medical illness for individuals with serious mental illness. Psychiatr Serv 64(1):51–57, 2013 23070062
Gomar JJ, Valls E, Radua J, et al; Cognitive Rehabilitation Study Group: A multisite, randomized controlled clinical trial of computerized cognitive remediation therapy for schizophrenia. Schizophr Bull 41(6):1387–1396, 2015 26006264
Grady PA, Gough LL: Self-management: a comprehensive approach to management of chronic conditions. Am J Public Health 104(8):e25–e31, 2014 24922170
Granholm EL, McQuaid JR, Holden JL: Cognitive-Behavioral Social Skills Training for Schizophrenia: A Practical Treatment Guide. New York, Guilford, 2016
Graus F, Titulaer MJ, Balu R, et al: A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391–404, 2016 26906964
Gray GE, Pi EH: Ethnicity and medication-induced movement disorders. J. Practical Psychiatry 4(5):259–264, 1998
Green MF: Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J Clin Psychiatry 77 (suppl 2):8–11, 2016 26919052
Greenblatt DJ, DiMascio A, Harmatz JS, et al: Pharmacokinetics and clinical effects of amantadine in drug-induced extrapyramidal symptoms. J Clin Pharmacol 17(11–12):704–708, 1977 336651
Greenhalgh AM, Gonzalez-Blanco L, Garcia-Rizo C, et al: Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve patients with nonaffective psychosis. Schizophr Res 179:57–63, 2017 27743650
Greenhalgh T, Robert G, Macfarlane F, et al: Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q 82(4):581–629, 2004
Gregory A, Mallikarjun P, Upthegrove R: Treatment of depression in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 211(4):198–204, 2017 28882827
Grigg J, Worsley R, Thew C, et al: Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl) 234(22):3279–3297, 2017 28889207
Grover S, Hazari N, Kate N: Combined use of clozapine and ECT: a review. Acta Neuropsychiatr 27(3):131–142, 2015 25697225
Grundy SM, Stone NJ, Bailey AL, et al: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73(24):e285–e350, 2018 30423393
Guenette MD, Hahn M, Cohn TA, et al: Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology (Berl) 226(1):1–12, 2013 23344556
Gurrera RJ, Caroff SN, Cohen A, et al: An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 72(9):1222–1228, 2011 21733489
Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN: A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol 37(1):67–71, 2017
Guy W (ed): ECDEU Assessment Manual for Psychopharmacology (Publ ADM 76-338.) Washington, DC, Center for Quality Assessment and Improvement in Mental Health, U.S. Department of Health, Education, and Welfare, 1976
Guyatt G, Gutterman D, Baumann MH, et al: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 129(1):174–181, 2006 16424429
Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group: Going from evidence to recommendations. BMJ 336(7652):1049–1051, 2008
Guyatt G, Eikelboom JW, Akl EA, et al: A guide to GRADE guidelines for the readers of JTH. J Thromb Haemost 11(8):1603–1608, 2013 23773710
Haddad PM, Brain C, Scott J: Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 5:43–62, 2014 25061342
Haldol decanoate injection (haloperidol) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, March 2019
Haldol lactate injection (haloperidol) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, March 2019
Hall D, Lee LW, Manseau MW, et al: Major mental illness as a risk factor for incarceration. Psychiatr Serv 70(12):1088–1093, 2019 31480926
Haloperidol [prescribing information]. Princeton, NJ, Sandoz, September 2008
Haloperidol lactate [prescribing information]. Greenville, SC, Pharmaceutical Associates, December 2008
Haloperidol lactate injection [prescribing information]. Schaumburg, IL, Sagent Pharmaceuticals, August 2011
Haloperidol lactate oral solution [prescribing information]. Greenville, SC, Pharmaceutical Associates, November 2016
Haloperidol tablets [prescribing information]. Princeton, NJ, Sandoz, July 2015
Hamann GL, Egan TM, Wells BG, Grimmig JE: Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. J Clin Psychiatry 51(12):502–504, 1990 1979555
Hamann J, Heres S: Why and how family caregivers should participate in shared decision making in mental health. Psychiatr Serv 70(5):418–421, 2019 30784381
Hamann J, Mendel R, Heres S, et al: How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed? Eur Neuropsychopharmacol 20(4):276–279, 2010 20133108
Hamann J, Kissling W, Heres S: Checking the plausibility of psychiatrists? Arguments for not prescribing depot medication. Eur Neuropsychopharmacol 24(9):1506–1510, 2014 25037772
Harding KJ, Rush AJ, Arbuckle M, et al: Measurement-based care in psychiatric practice: a policy framework for implementation. J Clin Psychiatry 72(8):1136–1143, 2011
Hardy K: Cognitive behavioral therapy for psychosis (CBTp). Alexandria, VA, National Association of State Mental Health Program Directors, 2019. Available at: www.nasmhpd.org/sites/default/files/DH-CBTp_ Fact_Sheet.pdf. Accessed April 12, 2019.
Harkavy-Friedman JM, Kimhy D, Nelson EA, et al: Suicide attempts in schizophrenia: the role of command auditory hallucinations for suicide. J Clin Psychiatry 64(8):871–874, 2003 12927000
Harris A, Chen W, Jones S, et al: Community treatment orders increase community care and delay readmission while in force: results from a large population-based study. Aust N Z J Psychiatry 53(3):228–235, 2019 29485289
Hartung D, Low A, Jindai K, et al: Interventions to improve pharmacological adherence among adults with psychotic spectrum disorders and bipolar disorder: a systematic review. Psychosomatics 58(2):101–112, 2017 28139249
Hartz SM, Pato CN, Medeiros H, et al; Genomic Psychiatry Cohort Consortium: Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 71(3):248–254, 2014 24382686
Harvey PD: Assessment of everyday functioning in schizophrenia. Innov Clin Neurosci 8(5):21–24, 2011 21686144
Harvey PD, McGurk SR, Mahncke H, Wykes T: Controversies in computerized cognitive training. Biol Psychiatry Cogn Neurosci Neuroimaging 3(11):907–915, 2018 30197048
Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13(5):318–378, 2012
Hasan A, Falkai P, Wobrock T, et al; WFSBP Task Force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14(1):2–44, 2013
Hasan A, Falkai P, Wobrock T, et al; WFSBP Task Force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 16(3):142–170, 2015
Hasson-Ohayon I, Roe D, Kravetz S: A randomized controlled trial of the effectiveness of the Illness Management and Recovery Program. Psychiatr Serv 58(11):1461–1466, 2007 17978257
Hatch A, Docherty JP, Carpenter D, et al: Expert consensus survey on medication adherence in psychiatric patients and use of a digital medicine system. J Clin Psychiatry 78(7):e803–e812, 2017 28541648
Hatcher-Martin JM, Armstrong KA, Scorr LM, Factor SA: Propranolol therapy for tardive dyskinesia: a retrospective examination. Parkinsonism Relat Disord 32:124–126, 2016 27622970
Hauser P, Kern S: Psychiatric and substance use disorders co-morbidities and hepatitis C: diagnostic and treatment implications. World J Hepatol 7(15):1921–1935, 2015
Hauser RA, Factor SA, Marder SR, et al: KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 174(5):476–484, 2017 28320223
Hauser RA, Fernandez HH, Stamler D, et al: 45 Long-term treatment with deutetrabenazine is associated with continued improvement in tardive dyskinesia: results from an open-label extension study. CNS Spectr 24(1):200–201, 2019 30859973
Hawton K, Sutton L, Haw C, et al: Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 187:9–20, 2005
Hayes JF, Marston L, Walters K, et al: Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry 211(3):175–181, 2017 28684403
Hazlehurst JM, Armstrong MJ, Sherlock M, et al: A comparative quality assessment of evidence-based clinical guidelines in endocrinology. Clin Endocrinol (Oxf) 78(2):183–190, 2013 22624723
He H, Lu J, Yang L, et al: Repetitive transcranial magnetic stimulation for treating the symptoms of schizophrenia: a PRISMA compliant meta-analysis. Clin Neurophysiol 128(5):716–724, 2017 28315614
He M, Deng C, Huang XF: The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs 27(6):423–434, 2013 23640535
Heilä H, Haukka J, Suvisaari J, Lönnqvist J: Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med 35(5):725–732, 2005 15918349
Helfer B, Samara MT, Huhn M, et al: Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 173(9):876–886, 2016 27282362
Helle S, Ringen PA, Melle I, et al: Cannabis use is associated with 3years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N=1119). Schizophr Res 170(1):217–221, 2016 26682958
Henderson DC, Vincenzi B, Andrea NV, et al: Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2(5):452–464, 2015
Heres S, Hamann J, Kissling W, Leucht S: Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 67(12):1948–1953, 2006 17194274
Heres S, Schmitz FS, Leucht S, Pajonk FG: The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 22(5):275–282, 2007 17690596
Heres S, Frobose T, Hamann J, et al: Patients’ acceptance of the deltoid application of risperidone long-acting injection. Eur Neuropsychopharmacol 22(12):897–901, 2012 22578781
Hiemke C, Dragicevic A, Gründer G, et al: Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26(2):156–160, 2004 15228157
Hiemke C, Bergemann N, Clement HW, et al: Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1-02):9–62, 2018 28910830
Higashi K, Medic G, Littlewood KJ, et al: Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 3(4):200–218, 2013 24167693
Higgins JM, San C, Lagnado G, et al: Incidence and management of clozapine-induced myocarditis in a large tertiary hospital. Can J Psychiatry 64(8):561–567, 2019
Hirsch L, Yang J, Bresee L, et al: Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf 40(9):771–781, 2017 28585153
Hirschtritt ME, Delucchi KL, Olfson M: Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993–2014. Prev Med Rep 9:49–54, 2017 29340270
Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M: Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 4(4):295–301, 2017 28237639
Hobkirk AL, Towe SL, Lion R, Meade CS: Primary and secondary HIV prevention among persons with severe mental illness: recent findings. Curr HIV/AIDS Rep 12(4):406–412, 2015
Hoffmann H, Jäckel D, Glauser S, et al: Long-term effectiveness of supported employment: 5-year follow-up of a randomized controlled trial. Am J Psychiatry 171(11):1183–1190, 2014 25124692
Hogarty GE, Kornblith SJ, Greenwald D, DiBarry AL, et al: Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates. Am J Psychiatry 154(11):1504–1513, 1997 9356557
Holt RI, Mitchell AJ: Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol 11(2):79–89, 2015 25445848
Honigfeld G, Arellano F, Sethi J, et al: Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 59 (suppl 3):3–7, 1998 9541331
Hor K, Taylor M: Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 24(4) (suppl):81–90, 2010
Horvitz-Lennon M, Donohue JM, Domino ME, Normand SL: Improving quality and diffusing best practices: the case of schizophrenia. Health Aff (Millwood) 28(3):701–712, 2009
Horvitz-Lennon M, Mattke S, Predmore Z, Howes OD: The role of antipsychotic plasma levels in the treatment of schizophrenia. Am J Psychiatry 174(5):421–426, 2017 28457153
Howard R, Rabins PV, Seeman MV, Jeste DV: Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus: the International Late-Onset Schizophrenia Group. Am J Psychiatry 157(2):172–178, 2000 10671383
Howells FM, Kingdon DG, Baldwin DS: Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review. Hum Psychopharmacol 32(5), 2017
Howes OD, McCutcheon R, Agid O, et al: Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174(3):216–229, 2017 27919182
Hughes E, Bassi S, Gilbody S, et al: Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry 3(1):40–48, 2016
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al: Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202):939–951, 2019 31303314 [Erratum Lancet 394(10202):918, 2019 31526735]
Huhtaniska S, Jääskeläinen E, Hirvonen N, et al: Long-term antipsychotic use and brain changes in schizophrenia—a systematic review and meta-analysis. Hum Psychopharmacol 32(2), 2017
Hui CLM, Honer WG, Lee EHM, et al: Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 5(5):432–442, 2018 29551618
Hunt GE, Siegfried N, Morley K, et al: Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev Oct 3(10):CD001088, 2013 24092525
Hunt GE, Large MM, Cleary M, et al: Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: systematic review and meta-analysis. Drug Alcohol Depend 191:234–258, 2018 30153606
Hynes C, Keating D, McWilliams S, et al: Glasgow Antipsychotic Side-effects Scale for clozapine: development and validation of a clozapine-specific side-effects scale. Schizophr Res 168(1–2):505–513, 2015 26276305
Ince P, Haddock G, Tai S: A systematic review of the implementation of recommended psychological interventions for schizophrenia: rates, barriers, and improvement strategies. Psychol Psychother 89(3):324–350, 2016 26537838
Ingrezza (valbenazine) [prescribing information]. San Diego, CA, Neurocrine Biosciences, July 2019
Inskip HM, Harris EC, Barraclough B: Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry 172:35–37, 1998
Institute of Medicine: Improving the Quality of Health Care for Mental and Substance-Use Conditions. Washington, DC, National Academies Press, 2006. Available at: https://doi.org/10.17226/11470. Accessed October 3, 2019.
Institute of Medicine: Clinical Practice Guidelines We Can Trust. Washington, DC, National Academies Press, 2011
Institute of Medicine Committee on Quality of Health Care in America: Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC, National Academies Press, 2001. Available at: www.ncbi.nlm.nih.gov/books/NBK222274. Accessed March 28, 2017.
Invega (paliperidone) [product monograph]. Toronto, ON, Canada, Janssen, September 2018
Invega (paliperidone) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, January 2019
Invega Sustenna (paliperidone) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, July 2018a
Invega Sustenna (paliperidone) [product monograph]. Toronto, ON, Canada, Janssen, September 2018b
Invega Trinza (paliperidone) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, July 2018a
Invega Trinza (paliperidone) [product monograph]. Toronto, ON, Canada, Janssen, September 2018b
Iorfino F, Scott EM, Carpenter JS, et al: Clinical stage transitions in persons aged 12 to 25 years presenting to early intervention mental health services with anxiety, mood, and psychotic disorders. JAMA Psychiatry Aug 28, 2019 Epub ahead of print
Ismail Z, Wessels AM, Uchida H, et al: Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry 20(1):53–60, 2012 21422906
Iyer S, Banks N, Roy MA, et al: A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics, part I: patient perspectives. Can J Psychiatry 58(5 suppl 1):14S–22S, 2013 23945063
Iyer SP, Spaeth-Rublee B, Pincus HA: Challenges in the operationalization of mental health quality measures: an assessment of alternatives. Psychiatr Serv 67(10):1057–1059, 2016
Jahshan C, Vinogradov S, Wynn JK, et al: A randomized controlled trial comparing a “bottom-up” and “top-down” approach to cognitive training in schizophrenia. J Psychiatr Res 109:118–125, 2019 30529836
Jann MW, Ereshefsky L, Saklad SR: Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 10(4):315–333, 1985 2864156
Janssen EM, McGinty EE, Azrin ST, et al: Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness. Gen Hosp Psychiatry 37(3):199–222, 2015 25881768
Jauhar S, McKenna PJ, Radua J, et al: Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 204(1):20–29, 2014 24385461
Jehan S, Myers AK, Zizi F, et al: Obesity, obstructive sleep apnea and type 2 diabetes mellitus: epidemiology and pathophysiologic insights. Sleep Med Disord 2(3):52–58, 2018 30167574
Jensen KG, Correll CU, Rudå D, et al: Cardiometabolic adverse effects and its predictors in children and adolescents with first-episode psychosis during treatment with quetiapine-extended release versus aripiprazole: 12-week results from the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) trial. J Am Acad Child Adolesc Psychiatry 58(11):1062–1078, 2019 30858012
Jin H, Mosweu I: The societal cost of schizophrenia: a systematic review. Pharmacoeconomics 35(1):25–42, 2017 27557994
Jinnah HA, Factor SA: Diagnosis and treatment of dystonia. Neurol Clin 33(1):77–100, 2015 25432724
Jordan G, Lutgens D, Joober R, et al: The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J Clin Psychiatry 75(6):e566–e572, 2014
Josiassen RC, Kane JM, Liang GS, et al: Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder. Psychopharmacol Bull 47(3):61–68, 2017 28839341
Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, et al: Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology (Berl) 234(17):2563–2570, 2017 28567698
Kaba F, Lewis A, Glowa-Kollisch S, et al: Solitary confinement and risk of self-harm among jail inmates. Am J Public Health 104(3):442–447, 2014 24521238
Kahn RS, Winter van Rossum I, Leucht S, et al; OPTiMiSE study group: Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 5(10):797–807, 2018 30115598
Kaiser RM: Physiological and clinical considerations of geriatric patient care, in The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 5th Edition. Edited by Steffens DC, Blazer DG, Thakur ME. Arlington, VA, American Psychiatric Publishing, 2015, pp 33–59
Kalachnik JE, Sprague RL: The Dyskinesia Identification System Condensed User Scale (DISCUS): reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations. J Clin Psychol 49(2):177–189, 1993 8098048
Kane JM, Marder SR, Schooler NR, et al: Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 58(10):965–972, 2001 11576036
Kane JM, Kishimoto T, Correll CU: Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 12(3):216–226, 2013 24096780
Kane JM, Correll CU, Liang GS, et al: Efficacy of valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and schizophrenia or schizoaffective disorder. Psychopharmacol Bull 47(3):69–76, 2017 28839342
Kane JM, Schooler NR, Marcy P, et al: Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry 80(3):18m12546, 2019 31050233
Kang UJ, Burke RE, Fahn S: Natural history and treatment of tardive dystonia. Mov Disord 1(3):193–208, 1986 2904118
Kaplan J, Schwartz AC, Ward MC: Clozapine-associated aspiration pneumonia: case series and review of the literature. Psychosomatics 59(2):199–203, 2018 28992957
Kapoor R, Trestman R: Mental health effects of restrictive housing, in Restrictive Housing in the U.S.: Issues, Challenges, and Future Directions. Washington, DC, National Institute of Justice, 2016, pp 199–232. Available at www.ncjrs.gov/pdffiles1/nij/250315.pdf. Accessed October 4, 2019.
Kates J, Rockland LH: Supportive psychotherapy of the schizophrenic patient. Am J Psychother 48(4):543–561, 1994 7872417
Kato Y, Umetsu R, Abe J, et al: Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports. J Pharm Health Care Sci 1:15, 2015 26819726
Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276, 1987
Kazamatsuri H, Chien C, Cole JO: Treatment of tardive dyskinesia, I: clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 27(1):95–99, 1972 4555831
Keck PEJr, Pope HG Jr, Cohen BM, et al: Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry 46(10):914–918, 1989 2572206
Keefe RS, Vinogradov S, Medalia A, et al: Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. J Clin Psychiatry 73(7):1016–1022, 2012 22687548
Keers R, Ullrich S, Destavola BL, Coid JW: Association of violence with emergence of persecutory delusions in untreated schizophrenia. Am J Psychiatry 171(3):332–339, 2014 24220644
Keller A, McGarvey EL, Clayton AH: Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther 32(1):43–52, 2006 16234225
Keller WR, Fischer BA, McMahon R, et al: Community adherence to schizophrenia treatment and safety monitoring guidelines. J Nerv Ment Dis 202(1):6–12, 2014 24375205
Kelley ME, Wan CR, Broussard B, et al: Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. Schizophr Res 171(1–3):62–67, 2016 26785806
Kelly DL, Freudenreich O, Sayer MA, Love RC: Addressing barriers to clozapine underutilization: a national effort. Psychiatr Serv 69(2):224–227, 2018 29032704
Kelly DL, Love RC: Psychiatric pharmacist’s role in overcoming barriers to clozapine use and improving management. Ment Health Clin 9(2):64–69, 2019 30842912
Kelly JT, Zimmermann RL, Abuzzahab FS, Schiele BC: A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism. Pharmacology 12(2):65–73, 1974 4610599
Kemp K, Zelle H, Bonnie RJ: Embedding advance directives in routine care for persons with serious mental illness: implementation challenges. Psychiatr Serv 66(1):10–14, 2015 25554232
Kennedy JL, Altar CA, Taylor DL, et al: The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 29(2):63–76, 2014 23995856
Khan AA, Ashraf A, Baker D, et al: Clozapine and incidence of myocarditis and sudden death—long term Australian experience. Int J Cardiol 238:136–139, 2017 28343762
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 3(1):1–150, 2013
Kingdon D, Turkington D: CBT for psychosis: approaches families can use. Arlington, VA, National Alliance on Mental Illness, April 15, 2019. Available at: https://nami.org/Blogs/NAMI-Blog/April-2019/CBT-for-Psychosis-Approaches-Families-Can-Use. Accessed April 21, 2019.
Kinon BJ, Gilmore JA, Liu H, Halbreich UM: Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 28 (suppl s):55–68, 2003 12650681
Kinoshita Y, Furukawa TA, Kinoshita K, et al: Supported employment for adults with severe mental illness. Cochrane Database Syst Rev Sep 13(9):CD008297, 2013 24030739
Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD: The natural history of tardive dystonia: a long-term follow-up study of 107 cases. Brain 121 (Pt 11):2053–2066, 1998 9827766
Kirino E: Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics. Ann Gen Psychiatry 16:43, 2017 29209406
Kirschner M, Theodoridou A, Fusar-Poli P, et al: Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol 3(2):89–99, 2013 24167680
Kirsh B: Client, contextual and program elements influencing supported employment: a literature review. Community Ment Health J 52(7):809–820, 2016 27055809
Kisely S, Smith M, Lawrence D, et al: Inequitable access for mentally ill patients to some medically necessary procedures. CMAJ 176(6):779–784, 2007 17353530
Kisely S, Crowe E, Lawrence D: Cancer-related mortality in people with mental illness. JAMA Psychiatry 70(2):209–217, 2013 23247556
Kisely S, Baghaie H, Lalloo R, et al: A systematic review and meta-analysis of the association between poor oral health and severe mental illness. Psychosom Med 77(1):83–92, 2015
Kishi T, Matsunaga S, Iwata N: Mortality risk associated with long-acting injectable antipsychotics: a systematic review and meta-analyses of randomized controlled trials. Schizophr Bull 42(6):1438–1445, 2016a 27086079
Kishi T, Oya K, Iwata N: Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: a systematic review and meta-analysis of randomized controlled trials. Psychiatry Res 246:750–755, 2016b 27863801
Kishi T, Ikuta T, Matsui Y, et al: Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis. Psychol Med 49(5):772–779, 2019 29909790
Kishimoto T, Nitta M, Borenstein M, et al: Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74(10):957–965, 2013 24229745
Kishimoto T, Robenzadeh A, Leucht C, et al: Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40(1):192–213, 2014 23256986
Kishimoto T, Hagi K, Nitta M, et al: Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull 44(3):603–619, 2018 29868849
Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, et al: Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res 150(1):274–280, 2013 23953217
Klil-Drori AJ, Yin H, Abenhaim HA, et al: Prolactin-elevating antipsychotics and the risk of endometrial cancer. J Clin Psychiatry 78(6):714–719, 2017 28199787
Knegtering H, van den Bosch R, Castelein S, et al: Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology 33(6):711–717, 2008 18395353
Knoph KN, Morgan RJ III, Palmer BA, et al: Clozapine-induced cardiomyopathy and myocarditis monitoring: a systematic review. Schizophr Res 199:17–30, 2018 29548760
Koek RJ, Pi EH: Acute laryngeal dystonic reactions to neuroleptics. Psychosomatics 30(4):359–364, 1989 2572029
König P, Chwatal K, Havelec L, et al: Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 33(2):80–84, 1996 8927233
Koopmans AB, Vinkers DJ, Poulina IT, et al: No effect of dose adjustment to the CYP2D6 genotype in patients with severe mental illness. Front Psychiatry 9:349, 2018 30131727
Kopelovich SL, Hughes M, Monroe-DeVita MB, et al: Statewide implementation of cognitive behavioral therapy for psychosis through a learning collaborative model. Cognit Behav Pract 26(3):439–452, 2019a
Kopelovich SL, Strachan E, Sivec H, Kreider V: Stepped care as an implementation and service delivery model for cognitive behavioral therapy for psychosis. Community Ment Health J 55(5):755–767, 2019b 30623294
Kopelowicz A, Liberman RP, Zarate R: Recent advances in social skills training for schizophrenia. Schizophr Bull 32 (suppl 1):S12–S23, 2006 16885207
Kopelowicz A, Zarate R, Wallace CJ, et al: The ability of multifamily groups to improve treatment adherence in Mexican Americans with schizophrenia. Arch Gen Psychiatry 69(3):265–273, 2012 22393219
Koskinen J, Löhönen J, Koponen H, et al: Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36(6):1115–1130, 2010
Kotin J, Wilbert DE, Verburg D, Soldinger SM: Thioridazine and sexual dysfunction. Am J Psychiatry 133(1):82–85, 1976 1247127
Koytchev R, Alken RG, McKay G, Katzarov T: Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. Eur J Clin Pharmacol 51(2):183–187, 1996 8911886
Krakowski MI, Czobor P, Citrome L, et al: Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 63(6):622–629, 2006 16754835
Krakowski MI, Czobor P, Nolan KA: Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol 28(5):485–493, 2008 18794642
Krelstein MS: The role of mental health in the inmate disciplinary process: a national survey. J Am Acad Psychiatry Law 30(4):488–496, 2002
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT): The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 36(1):94–103, 2010
Kreyenbuhl J, Record EJ, Palmer-Bacon J: A review of behavioral tailoring strategies for improving medication adherence in serious mental illness. Dialogues Clin Neurosci 18(2):191–201, 2016 27489459
Kroeze WK, Hufeisen SJ, Popadak BA, et al: H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3):519–526, 2003 12629531
Kroon LA: Drug interactions with smoking. Am J Health Syst Pharm 64(18):1917–1921, 2007
Kugathasan P, Horsdal HT, Aagaard J, et al: Association of secondary preventive cardiovascular treatment after myocardial infarction with mortality among patients with schizophrenia. JAMA Psychiatry 75(12):1234–1240, 2018 30422158
Kuhnigk O, Slawik L, Meyer J, et al: Valuation and attainment of treatment goals in schizophrenia: perspectives of patients, relatives, physicians, and payers. J Psychiatr Pract 18(5):321–328, 2012 22995959
Kukla M, Bell MD, Lysaker PH: A randomized controlled trial examining a cognitive behavioral therapy intervention enhanced with cognitive remediation to improve work and neurocognition outcomes among persons with schizophrenia spectrum disorders. Schizophr Res 197:400–406, 2018 29422299
Lachkar Y, Bouassida W: Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol 18(2):129–133, 2007 17301614
Lagishetty CV, Deng J, Lesko LJ, et al: How informative are drug-drug interactions of gene-drug interactions? J Clin Pharmacol 56(10):1221–1231, 2016 27040602
La Grenade L, Graham D, Trontell A: Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 345(3):224–225, 2001 11463031
Lally J, Docherty MJ, MacCabe JH: Pharmacological interventions for clozapine-induced sinus tachycardia. Cochrane Database Syst Rev Jun 9(6):CD011566, 2016a 27277334
Lally J, Tully J, Robertson D, et al: Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 171(1–3):215–224, 2016b 26827129
Lally J, Ajnakina O, Stubbs B, et al: Hyperprolactinaemia in first episode psychosis: a longitudinal assessment. Schizophr Res 189:117–125, 2017a 28755878
Lally J, Malik S, Krivoy A, et al: The use of granulocyte colony-stimulating factor in clozapine rechallenge: a systematic review. J Clin Psychopharmacol 37(5):600–604, 2017b 28817489
Lally J, Malik S, Whiskey E, et al: Clozapine-associated agranulocytosis treatment with granulocyte colony-stimulating factor/granulocyte-macrophage colony-stimulating factor: a systematic review. J Clin Psychopharmacol 37(4):441–446, 2017c 28437295
Land R, Siskind D, McArdle P, et al: The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand 135(4):296–309, 2017 28155220
Landa Y: Cognitive behavioral therapy for psychosis (CBTp): an introductory manual for clinicians. New York, MIRECC VISN 2, 2019. Available at: www.mirecc.va.gov/visn2/docs/CBTp_Manual_VA_Yulia_Landa_ 2017.pdf. Accessed April 1, 2019.
Large MM, Nielssen O: Violence in first-episode psychosis: a systematic review and meta-analysis. Schizophr Res 125(2–3):209–220, 2011
Large M, Sharma S, Compton MT, et al: Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 68(6):555–561, 2011
Large M, Mullin K, Gupta P, et al: Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. Aust N Z J Psychiatry 48(5):418–432, 2014
Lariscy JT, Hummer RA, Rogers RG: Cigarette smoking and all-cause and cause-specific adult mortality in the United States. Demography 55(5):1855–1885, 2018 30232778
Laties AM, Flach AJ, Baldycheva I, et al: Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. J Psychopharmacol 29(1):69–79, 2015 25315830
Latimer E, Wynant W, Clark R, et al: Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec. Clin Schizophr Relat Psychoses 7(1):33–41, 2013 23367500
La Torre A, Conca A, Duffy D, et al: Sexual dysfunction related to psychotropic drugs: a critical review, part II: antipsychotics. Pharmacopsychiatry 46(6):201–208, 2013 23737244
Latuda (lurasidone) [prescribing information]. Marlborough, MA, Sunovion Pharmaceuticals, March 2018
Lauby-Secretan B, Scoccianti C, Loomis D, et al; International Agency for Research on Cancer Handbook Working Group: Body fatness and cancer: viewpoint of the IARC Working Group. N Engl J Med 375(8):794–798, 2016 27557308
Laursen TM, Wahlbeck K, Hällgren J, et al: Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One 8(6):e67133, 2013
Laursen TM, Nordentoft M, Mortensen PB: Excess early mortality in schizophrenia. Annu Rev Clin Psychol 10:425–448, 2014 24313570
Lawrence D, Kisely S, Pais J: The epidemiology of excess mortality in people with mental illness. Can J Psychiatry 55(12):752–760, 2010 21172095
Lawson W, Johnston S, Karson C, et al: Racial differences in antipsychotic use: claims database analysis of Medicaid-insured patients with schizophrenia. Ann Clin Psychiatry 27(4):242–252, 2015 26554365
Lean M, Fornells-Ambrojo M, Milton A, et al: Self-management interventions for people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry 214(5):260–268, 2019 30898177
Le Boutillier C, Leamy M, Bird VJ, et al: What does recovery mean in practice? A qualitative analysis of international recovery-oriented practice guidance. Psychiatr Serv 62(12):1470–1476, 2011
Lecomte T, Leclerc C, Wykes T: Group CBT for Psychosis: A Guidebook for Clinicians. New York, Oxford University Press, 2016, p 296
Lee EE, Liu J, Tu X, et al: A widening longevity gap between people with schizophrenia and general population: a literature review and call for action. Schizophr Res 196:9–13, 2018 28964652
Lee WM, Stravitz RT, Larson AM: AASLD position paper: the management of acute liver failure: update 2011. Alexandria, VA, American Association for the Study of Liver Diseases, 2011. Available at: www.aasld.org/sites/default/files/2019-06/AcuteLiverFailureUpdate201journalformat1.pdf. Accessed March 31, 2017.
Legge SE, Hamshere ML, Ripke S, et al: Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Mol Psychiatry 22(10):1502–1508, 2017 27400856
Leucht S, Kane JM, Kissling W, et al: Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry 187:366–371, 2005 16199797
Leucht S, Tardy M, Komossa K, et al: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379(9831):2063–2071, 2012 22560607
Leucht S, Cipriani A, Spineli L, et al: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962, 2013 23810019
Leucht S, Samara M, Heres S, et al: Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40(2):314–326, 2014 24493852
Leucht S, Samara M, Heres S, et al: Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 41(6):1397–1402, 2015 25841041
Leucht S, Leucht C, Huhn M, et al: Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174(10):927–942, 2017 28541090
Leung JG, Breden EL: Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 45(4):525–531, 2011 21487088
Leung JG, Hasassri ME, Barreto JN, et al: Characterization of admission types in medically hospitalized patients prescribed clozapine. Psychosomatics 58(2):164–172, 2017 28153339
Leung JG, Cusimano J, Gannon JM, et al: Addressing clozapine under-prescribing and barriers to initiation: a psychiatrist, advanced practice provider, and trainee survey. Int Clin Psychopharmacol 34(5):247–256, 2019 31107831
Levitan B, Markowitz M, Mohamed AF, et al: Patients’ preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatr Serv 66(7):719–726, 2015 25772762
Levounis P, Arnaout B, Marienfeld C: Motivational Interviewing for Clinical Practice. Arlington, VA, American Psychiatric Association Publishing, 2017
Lewis CC, Boyd M, Puspitasari A, et al: Implementing measurement-based care in behavioral health: a review. JAMA Psychiatry 76(3):324–335, 2019 30566197
Lewis-Fernández R, Aggarwal NK, Hinton L, et al (eds): DSM-5® Handbook on the Cultural Formulation Interview. Arlington, VA, American Psychiatric Association Publishing, 2016
Lexicomp: Lexicomp database. Riverwoods IL, Wolters Kluwer Health, 2019. Available at: http://online.lexi.com. Accessed January 4, 2019.
Liang CS, Ho PS, Shen LJ, et al: Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophr Res 119(1–3):138–144, 2010 20299191
Liao TV, Phan SV: Acute hyperglycemia associated with short-term use of atypical antipsychotic medications. Drugs 74(2):183–194, 2014 24399515
Lieberman JA, First MB: Psychotic disorders. N Engl J Med 379(3):270–280, 2018
Lieberman JA, Saltz BL, Johns CA, et al: The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158:503–510, 1991 1675900
Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR: Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev (1):CD001950, 2002 11869614
Lima AR, Bacalcthuk J, Barnes TR, Soares-Weiser K: Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev Oct 18(4):CD001946, 2004 15495022
Lindenmayer JP: Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr Dis Treat 6:261–267, 2010 20628628
Lindström E, Lewander T, Malm U, et al: Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia: clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry 55 (suppl 44):5–69, 2001 11860666
Lingjaerde O, Ahlfors UG, Bech P, et al: The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100, 1987 2887090
Lopez LV, Kane JM: Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature. Schizophr Res 147(2–3):368–374, 2013 23664462
Lopez LV, Shaikh A, Merson J, et al: Accuracy of clinician assessments of medication status in the emergency setting: a comparison of clinician assessment of antipsychotic usage and plasma level determination. J Clin Psychopharmacol 37(3):310–314, 2017 28353490
López-Moríñigo JD, Ramos-Ríos R, David AS, Dutta R: Insight in schizophrenia and risk of suicide: a systematic update. Compr Psychiatry 53(4):313–322, 2012
Lopez-Morinigo JD, Fernandes AC, Chang CK, et al: Suicide completion in secondary mental healthcare: a comparison study between schizophrenia spectrum disorders and all other diagnoses. BMC Psychiatry 14:213, 2014
Lowe CM, Grube RR, Scates AC: Characterization and clinical management of clozapine-induced fever. Ann Pharmacother 41(10):1700–1704, 2007 17785616
Loxapac (loxapine hydrochloride) [product monograph]. Boucherville, QC, Canada, Sandoz Canada, July 2014
Loxitane (loxapine) [prescribing information]. Corona, CA, Watson Pharma, February 2017
Luciano A, Bond GR, Drake RE: Does employment alter the course and outcome of schizophrenia and other severe mental illnesses? A systematic review of longitudinal research. Schizophr Res 159(2–3):312–321, 2014 25278105
Lucksted A, Medoff D, Burland J, et al: Sustained outcomes of a peer-taught family education program on mental illness. Acta Psychiatr Scand 127(4):279–286, 2013 22804103
Lum A, Skelton E, Wynne O, Bonevski B: A systematic review of psychosocial barriers and facilitators to smoking cessation in people living with schizophrenia. Front Psychiatry 9:565, 2018 30459658
MacEwan JP, Forma FM, Shafrin J, et al: Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J Manag Care Spec Pharm 22(11):1349–1361, 2016a 27783548
MacEwan JP, Kamat SA, Duffy RA, et al: Hospital readmission rates among patients with schizophrenia treated with long-acting injectables or oral antipsychotics. Psychiatr Serv 67(11):1183–1188, 2016b 27417897
MacKinnon R, Michels R, Buckley P: The Psychiatric Interview in Clinical Practice, 3rd Edition. Arlington, VA, American Psychiatric Association Publishing, 2016
Maeda K, Sugino H, Akazawa H, et al: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350(3):589–604, 2014 24947465
Maher S, Cunningham A, O’Callaghan N, et al: Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. Ther Adv Psychopharmacol 6(3):178–184, 2016 27354906
Mahmood S, Booker I, Huang J, Coleman CI: Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 33(1):90–94, 2013 23277264
Malla A, McGorry P: Early intervention in psychosis in young people: a population and public health perspective. Am J Public Health 109(S3):S181–S184, 2019 31242015
Man WH, Colen-de Koning JC, Schulte PF, et al: The effect of glycopyrrolate on nocturnal sialorrhea in patients using clozapine: a randomized, crossover, double-blind, placebo-controlled trial. J Clin Psychopharmacol 37(2):155–161, 2017 28129312
Mangurian C, Newcomer JW, Modlin C, Schillinger D: Diabetes and cardiovascular care among people with severe mental illness: a literature review. J Gen Intern Med 31(9):1083–1091, 2016 27149967
Manu P, Dima L, Shulman M, et al: Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand 132(2):97–108, 2015 26016380
Manu P, Lapitskaya Y, Shaikh A, Nielsen J: Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases. Am J Ther 25(2):e218–e223, 2018 29505490
Mar PL, Raj SR: Orthostatic hypotension for the cardiologist. Curr Opin Cardiol 33(1):66–72, 2018 28984649
Marcus SM, Medoff D, Fang LJ, et al: Generalizability in the Family-to-Family education program randomized waitlist-control trial. Psychiatr Serv 64(8):754–763, 2013 23633161
Marino LA, Dixon LB: An update on supported employment for people with severe mental illness. Curr Opin Psychiatry 27(3):210–215, 2014 24613982
Marques TR, Smith S, Bonaccorso S, et al: Sexual dysfunction in people with prodromal or first-episode psychosis. Br J Psychiatry 201:131–136, 2012 22700081
Marshall M, Lockwood A: Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev (2):CD001089, 2000 10796415
Marshall M, Rathbone J: Early intervention for psychosis. Cochrane Database Syst Rev Jun 15(6):CD004718, 2011 21678345
Marshall T, Goldberg RW, Braude L, et al: Supported employment: assessing the evidence. Psychiatr Serv 65(1):16–23, 2014 24247197
Martin-Latry K, Goumy MP, Latry P, et al: Psychotropic drugs use and risk of heat-related hospitalisation. Eur Psychiatry 22(6):335–338, 2007 17513091
Martino D, Karnik V, Osland S, et al: Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and meta-analysis. Can J Psychiatry 63(11):706743718777392, 2018 Epub ahead of print
Mason M, Cates CJ, Smith I: Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev Jul 14(7):CD011090, 2015 26171909
Matsuo M, Sano I, Ikeda Y, et al: Intraoperative floppy-iris syndrome associated with use of antipsychotic drugs. Can J Ophthalmol 51(4):294–296, 2016 27521670
Maust DT, Lin LA, Blow FC: Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv 70(2):97–106, 2019
Mayoral F, Berrozpe A, de la Higuera J, et al: Efficacy of a family intervention program for prevention of hospitalization in patients with schizophrenia: a naturalistic multicenter controlled and randomized study in Spain. Rev Psiquiatr Salud Ment 8(2):83–91, 2015 25017624
McCrary KJ, Weiden PJ, Gever MP: Schizophrenia: understanding your illness. Jacksonville, Florida Self-Directed Care Program District 4, 2019. Available at: www.floridasdc4.com/01_understanding.pdf. Accessed March 30, 2019.
McCutcheon R, Beck K, D’Ambrosio E, et al: Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand 137(1):39–46, 2018 29072776
McDonagh MS, Dana T, Selph S, et al: Treatments for adults with schizophrenia: a systematic review [Comparative Effectiveness Review No 198, AHRQ Publ No 17(18)-EHC031-EF]. Rockville, MD, Agency for Healthcare Research and Quality, October 2017. Available at: https://effectivehealthcare.ahrq.gov/ topics/schizophrenia-adult/research-2017. Accessed May 10, 2019.
McDonald-McGinn DM, Sullivan KE, Marino B, et al: 22q11.2 deletion syndrome. Nat Rev Dis Primers 1:15071, 2015 27189754
McDowell C, Fossey E: Workplace accommodations for people with mental illness: a scoping review. J Occup Rehabil 25(1):197–206, 2015 24841728
McEvoy JP: A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. J Clin Psychiatry 48 (suppl):20–23, 1987 2887553
McEvoy JP, McCue M, Freter S: Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia. Clin Ther 9(4):429–433, 1987 2886223
McEvoy JP, Lieberman JA, Stroup TS, et al; CATIE Investigators: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163(4):600–610, 2006 16585434
McEvoy J, Gandhi SK, Rizio AA, et al: Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res 28(12):3303–3312, 2019
McFarlane WR: Family interventions for schizophrenia and the psychoses: a review. Fam Process 55(3):460–482, 2016 27411376
McGinty EE, Baller J, Azrin ST, et al: Interventions to address medical conditions and health-risk behaviors among persons with serious mental illness: a comprehensive review. Schizophr Bull 42(1):96–124, 2016 26221050
McGrath J, Saha S, Chant D, Welham J: Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67–76, 2008
McGurk SR, Twamley EW, Sitzer DI, et al: A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 164(12):1791–1802, 2007 18056233
McGurk SR, Mueser KT, Xie H, et al: Cognitive enhancement treatment for people with mental illness who do not respond to supported employment: a randomized controlled trial. Am J Psychiatry 172(9):852–861, 2015 25998278
McGurk SR, Mueser KT, Xie H, et al: Cognitive remediation for vocational rehabilitation nonresponders. Schizophr Res 175(1–3):48–56, 2016 27209526
McNiel DE, Eisner JP, Binder RL: The relationship between command hallucinations and violence. Psychiatr Serv 51(10):1288–1292, 2000 11013329
Medalia A: Seven common questions about cognitive remediation. New York, Lieber Recovery Clinic, 2019. Available at: www.lieberclinic.com/cognitive-remediation. Accessed April 12, 2019.
Medalia A, Herlands T, Saperstein A, Revheim N: Cognitive Remediation for Psychological Disorders: Therapist Guide (Treatments That Work), 2nd Edition. New York, Oxford University Press, 2018
Medalia A, Erlich MD, Soumet-Leman C, Saperstein AM: Translating cognitive behavioral interventions from bench to bedside: the feasibility and acceptability of cognitive remediation in research as compared to clinical settings. Schizophr Res 203:49–54, 2019 28768601
Mehta SH, Morgan JC, Sethi KD: Drug-induced movement disorders. Neurol Clin 33(1):153–174, 2015 25432728
Meldrum ML, Kelly EL, Calderon R, et al: Implementation status of assisted outpatient treatment programs: a national survey. Psychiatr Serv 67(6):630–635, 2016 26828396
Melkote R, Singh A, Vermeulen A, et al: Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. Schizophr Res 201:324–328, 2018 29804929
Meltzer HY, Alphs L, Green AI, et al; International Suicide Prevention Trial Study Group: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60(1):82–91, 2003 12511175
Melzer-Ribeiro DL, Rigonatti SP, Kayo M, et al: Efficacy of electroconvulsive therapy augmentation for partial response to clozapine: a pilot randomized ECT–sham controlled trial. Archives of Clinical Psychiatry (São Paulo) 44(2):45–50, 2017
Mental Health America: Mental Health America. Alexandria, VA, Mental Health America, 2019. Available at: www.mhanational.org. Accessed September 29, 2019.
Mentzel TQ, Lieverse R, Bloemen O, et al; Genetic Risk and Outcome of Psychosis (GROUP) Investigators: High incidence and prevalence of drug-related movement disorders in young patients with psychotic disorders. J Clin Psychopharmacol 37(2):231–238, 2017 28141621
Mentzel TQ, van der Snoek R, Lieverse R, et al: Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis. J Clin Psychiatry 79(6):17r11852, 2018
Metcalfe JD, Drake RE, Bond GR: Economic, labor, and regulatory moderators of the effect of individual placement and support among people with severe mental illness: a systematic review and meta-analysis. Schizophr Bull 44(1):22–31, 2018 29036727
Metzner JL: Class action litigation in correctional psychiatry. J Am Acad Psychiatry Law 30(1):19–29, discussion 30–32, 2002
Metzner JL: Mental health considerations for segregated inmates, in Standards for Health Services in Prisons. Chicago, IL, National Commission on Correctional Healthcare, 2003, pp 241–254
Metzner JL, Fellner J: Solitary confinement and mental illness in U.S. prisons: a challenge for medical ethics. J Am Acad Psychiatry Law 38(1):104–108, 2010 20305083
Meyer JM: Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectr 18 (suppl 1):58–67, quiz 68, 2013
Meyer JM: Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectr 22(S1):14–28, 2017 29350127
Meyer JM, Koro CE: The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70(1):1–17, 2004 15246458
MGH Center for Women’s Mental Health: National pregnancy registry for atypical antipsychotics. Boston, MA, MGH Center for Women’s Mental Health, 2019. Available at: https://womensmentalhealth.org/research/pregnancyregistry/atypicalantipsychotic. Accessed September 21, 2019.
Michl J, Scharinger C, Zauner M, et al: A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities. Eur Neuropsychopharmacol 24(9):1463–1474, 2014 25044049
Micromedex: IBM Micromedex® Web Applications Access. Greenwood Village, CO, IBM Watson Health, 2019. Available at: www.micromedexsolutions.com. Accessed January 4, 2019.
Miller DD, McEvoy JP, Davis SM, et al: Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 80(1):33–43, 2005 16171976
Miller DD, Caroff SN, Davis SM, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 193(4):279–288, 2008 18827289
Miller DT, Adam MP, Aradhya S, et al: Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 86(5):749–764, 2010 20466091
Mindham RH, Gaind R, Anstee BH, Rimmer L: Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced parkinsonism. Psychol Med 2(4):406–413, 1972 4571143
Mintz AR, Dobson KS, Romney DM: Insight in schizophrenia: a meta-analysis. Schizophr Res 61(1):75–88, 2003 12648738
Misiak B, Stanczykiewicz B, Laczmanski L, Frydecka D: Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: a systematic review and meta-analysis. Schizophr Res 190:18–27, 2017 28325572
Mitchell AJ, Delaffon V, Vancampfort D, et al: Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 42(1):125–147, 2012 21846426
Mitchell AJ, Vancampfort D, De Herdt A, et al: Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull 39(2):295–305, 2013a 22927670
Mitchell AJ, Vancampfort D, Sweers K, et al: Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: a systematic review and meta-analysis. Schizophr Bull 39(2):306–318, 2013b 22207632
Mizuno Y, Suzuki T, Nakagawa A, et al: Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 40(6):1385–1403, 2014 24636967
Moban (molindone) [prescribing information]. Malvern, PA, Endo Pharmaceuticals, February 2017
Moberg PJ, Richman MJ, Roalf DR, et al: Neurocognitive functioning in patients with 22q11.2 deletion syndrome: a meta-analytic review. Behav Genet 48(4):259–270, 2018 29922984
Modini M, Tan L, Brinchmann B, et al: Supported employment for people with severe mental illness: systematic review and meta-analysis of the international evidence. Br J Psychiatry 209(1):14–22, 2016 27103678
Mohamed S, Rosenheck R, McEvoy J, et al: Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 35(2):336–346, 2009 18586692
Molindone hydrochloride tablets [prescribing information]. Middlesex, NJ, CorePharma, August 2014
Molindone hydrochloride tablets [prescribing information]. Laurelton, NY, Epic Pharma, April 2018
Moncrieff J, Steingard S: A critical analysis of recent data on the long-term outcome of antipsychotic treatment. Psychol Med 49(5):750–753, 2019 30563582
Monroe-DeVita M, Morse G, Bond GR: Program fidelity and beyond: multiple strategies and criteria for ensuring quality of assertive community treatment. Psychiatr Serv 63(8):743–750, 2012 22508406
Monuteaux MC, Lee LK, Hemenway D, et al: Firearm ownership and violent crime in the U.S.: an ecologic study. Am J Prev Med 49(2):207–214, 2015 26091930
Moons T, de Roo M, Claes S, Dom G: Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12(8):1193–1211, 2011 21843066
Moore S, Shiers D, Daly B, et al: Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care. Acta Psychiatr Scand 132(2):109–121, 2015 25958971
Moreno-Küstner B, Martín C, Pastor L: Prevalence of psychotic disorders and its association with methodological issues: a systematic review and meta-analyses. PLoS One 13(4):e0195687, 2018 29649252
Morgan VA, Morgan F, Galletly C, et al: Sociodemographic, clinical and childhood correlates of adult violent victimisation in a large, national survey sample of people with psychotic disorders. Soc Psychiatry Psychiatr Epidemiol 51(2):269–279, 2016 26581211
Moriarty DG, Zack MM, Kobau R: The Centers for Disease Control and Prevention’s Healthy Days Measures: population tracking of perceived physical and mental health over time. Health Qual Life Outcomes 1:37, 2003
Morosini PL, Magliano L, Brambilla L, et al: Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 101(4):323–329, 2000 10782554
Morrato EH, Newcomer JW, Kamat S, et al: Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32(6):1037–1042, 2009 19244091
Morrison AP: A manualised treatment protocol to guide delivery of evidence-based cognitive therapy for people with distressing psychosis: learning from clinical trials. Psychosis 9(3):271–281, 2017
Morrison AP, Pyle M, Gumley A, et al; FOCUS trial group: Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. Lancet Psychiatry 5(8):633–643, 2018 30001930
Morrissey JP, Domino ME, Cuddeback GS: Expedited Medicaid enrollment, mental health service use, and criminal recidivism among released prisoners with severe mental illness. Psychiatr Serv 67(8):842–849, 2016 26975522
Morse G, Glass AM, Monroe-DeVita M: ACT and recovery: what we know about their compatibility. Adm Policy Ment Health 43(2):219–230, 2016 25638223
Mościcki EK, Clarke DE, Kuramoto SJ, et al: Testing DSM-5 in routine clinical practice settings: feasibility and clinical utility. Psychiatr Serv 64(10):952–960, 2013 23852272
Mosheva M, Korotkin L, Gur RE, et al: Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review. Eur Child Adolesc Psychiatry Apr 4, 2019 Epub ahead of print
Mountjoy CQ, Baldacchino AM, Stubbs JH: British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry 156(1):158–159, 1999
Mueller DR, Schmidt SJ, Roder V: One-year randomized controlled trial and follow-up of integrated neurocognitive therapy for schizophrenia outpatients. Schizophr Bull 41(3):604–616, 2015 25713462
Mueser KT, Corrigan PW, Hilton DW, et al: Illness management and recovery: a review of the research. Psychiatr Serv 53(10):1272–1284, 2002 12364675
Mueser KT, Clark RE, Haines M, et al: The Hartford study of supported employment for persons with severe mental illness. J Consult Clin Psychol 72(3):479–490, 2004 15279531
Mueser KT, Pratt SI, Bartels SJ, et al: Randomized trial of social rehabilitation and integrated health care for older people with severe mental illness. J Consult Clin Psychol 78(4):561–573, 2010 20658812
Mueser KT, Deavers F, Penn DL, Cassisi JE: Psychosocial treatments for schizophrenia. Annu Rev Clin Psychol 9:465–497, 2013 23330939
Mueser KT, Penn DL, Addington J, et al: The NAVIGATE program for first-episode psychosis: rationale, overview, and description of psychosocial components. Psychiatr Serv 66(7):680–690, 2015 25772766
Mukundan A, Faulkner G, Cohn T, Remington G: Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev Dec 8(12):CD006629, 2010 21154372
Munetz MR, Benjamin S: How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 39(11):1172–1177, 1988
Muralidharan A, Brown CH,Peer JE, et al: Living Well: an intervention to improve medical illness self- management among individuals with serious mental illness. Psychiatr Serv 70(1):19–25, 2019 30353790
Murray H, Wortzel HS: Psychiatric advance directives: origins, benefits, challenges, and future directions. J Psychiatr Pract 25(4):303–307, 2019 31291211
Myles H, Myles N, Antic NA, et al: Obstructive sleep apnea and schizophrenia: a systematic review to inform clinical practice. Schizophr Res 170(1):222–225, 2016
Myles N, Newall HD, Curtis J, et al: Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis. J Clin Psychiatry 73(4):468–475, 2012
Myles N, Myles H, Clark SR, et al: Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: a systematic review of the literature and clinical recommendations. Aust N Z J Psychiatry 51(10):980–989, 2017 28747065
Myles N, Myles H, Xia S, et al: Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand 138(2):101–109, 2018 29786829
Myles N, Myles H, Xia S, et al: A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia. Aust N Z J Psychiatry 53(5):403–412, 2019 30864459
Naber D, Leppig M, Grohmann R, Hippius H: Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia: a retrospective study of 387 patients. Psychopharmacology (Berl) 99(suppl):S73–S76, 1989 2813668
Narrow WE, Clarke DE, Kuramoto SJ, et al: DSM-5 field trials in the United States and Canada, part III: development and reliability testing of a cross-cutting symptom assessment for DSM-5. Am J Psychiatry 170(1):71–82, 2013
Naslund JA, Aschbrenner KA, Scherer EA, et al: Lifestyle intervention for people with severe obesity and serious mental illness. Am J Prev Med 50(2):145–153, 2016 26385164
Nasrallah HA, Tandon R: Classic antipsychotic medications, in The American Psychiatric Association Publishing Textbook of Psychopharmacology, 5th Edition. Edited by Schatzberg AF, Nemeroff CB. Arlington, VA, American Psychiatric Association Publishing, 2017, pp 603–621
Nasser AF, Henderson DC, Fava M, et al: Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia. J Clin Psychopharmacol 36(2):130–140, 2016 26862829
National Alliance on Mental Illness: NAMI Family & Friends. Arlington, VA, National Alliance on Mental Illness, 2019a. Available at: www.nami.org/find-support/nami-programs/nami-family-friends. Accessed September 29, 2019.
National Alliance on Mental Illness: NAMI Family-to-Family. Arlington, VA, National Alliance on Mental Illness, 2019b. Available at: www.nami.org/Find-Support/NAMI-Programs/NAMI-Family-to-Family. Accessed April 11, 2019.
National Cancer Institute: Quit smoking. Bethesda, MD, National Cancer Institute, 2019. Available at: https://smokefree.gov/quit-smoking. Accessed December 31, 2018.
National Commission on Correctional Health Care: Position statement: solitary confinement (isolation). J Correct Health Care 22(3):257–263, 2016 27302711
National Institute for Health and Care Excellence: Psychosis and schizophrenia in adults: prevention and management: updated edition 2014. London, National Collaborating Centre for Mental Health, 2014. Available at: www.nice.org.uk/guidance/cg178. Accessed May 7, 2019.
National Institute of Mental Health: What is RAISE? Bethesda, MD, National Institute of Mental Health, 2019a. Available at: www.nimh.nih.gov/health/topics/schizophrenia/raise/what-is-raise.shtml. Accessed October 1, 2019.
National Institute of Mental Health: Recovery After an Initial Schizophrenia Episode (RAISE): State Health Administrators and Clinics. Bethesda, MD, National Institute of Mental Health, 2019b. Available at: www.nimh.nih.gov/health/topics/schizophrenia/raise/state-health-administrators-and-clinics.shtml. Accessed on March 31, 2019.
Navane (thiothixene) [prescribing information]. New York, Pfizer, December 2010
NAVIGATE: NAVIGATE. Philadelphia, PA, NAVIGATE, 2019. Available at: http://navigateconsultants.org/manuals. Accessed May 6, 2020.
Nesvåg R, Knudsen GP, Bakken IJ, et al: Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study. Soc Psychiatry Psychiatr Epidemiol 50(8):1267–1276, 2015 25680837
Newcomer JW, Weiden PJ, Buchanan RW: Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry 74(11):1108–1120, 2013 24330898
Nielsen SM, Toftdahl NG, Nordentoft M, Hjorthøj C: Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study. Psychol Med 47(9):1668–1677, 2017 28166863
Niskanen P, Achté K, Jaskari M, et al: Results of a comparative double-blind study with clozapine and chlorpromazine in the treatment of schizophrenic patients. Psychiatria Fennica 307–313, 1974
Nordentoft M, Jeppesen P, Abel M, et al: OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis: one-year follow-up of a randomised controlled trial. Br J Psychiatry Suppl 43:s98–s106, 2002 12271808
Nordentoft M, Mortensen PB, Pedersen CB: Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry 68(10):1058–1064, 2011 21969462
Norman R, Lecomte T, Addington D, Anderson E: Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults. Can J Psychiatry 62(9):617–623, 2017
Novalis PN, Rojcewicz SJ, Peele R: Clinical Manual of Supportive Psychotherapy. Washington, DC, American Psychiatric Press, 1993, p 384
Nuplazid (10 and 34 mg pimavanserin) [prescribing information]. San Diego, CA, Acadia Pharmaceuticals, June 2018
Nuplazid (17 mg pimavanserin) [prescribing information]. San Diego, CA, Acadia Pharmaceuticals, June 2018
Oakley P, Kisely S, Baxter A, et al: Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis. J Psychiatr Res 102:245–253, 2018 29723811
O’Brien A: Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. Int J Geriatr Psychiatry 31(7):683–693, 2016 26679687
O’Brien CF, Jimenez R, Hauser RA, et al: NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord 30(12):1681–1687, 2015 26346941
Office for Civil Rights: Health information privacy: information related to mental and behavioral health, including opioid overdose. Washington, DC, U.S. Department of Health and Human Services, December 19, 2017a. Available at: www.hhs.gov/hipaa/for-professionals/special-topics/mental-health/index.html. Accessed November 18, 2018.
Office for Civil Rights: HIPAA privacy rule and sharing information related to mental health. Washington, DC, U.S. Department of Health and Human Services, December 19, 2017b. Available at: www.hhs.gov/sites/default/files/hipaa-privacy-rule-and-sharing-info-related-to-mental-health.pdf. Accessed November 18, 2018.
O’Keefe ML, Klebe KJ, Metzner J, et al: A longitudinal study of administrative segregation. J Am Acad Psychiatry Law 41(1):49–60, 2013 23503176
Olbert CM, Nagendra A, Buck B: Meta-analysis of black vs. white racial disparity in schizophrenia diagnosis in the United States: do structured assessments attenuate racial disparities? J Abnorm Psychol 127(1):104–115, 2018 29094963
Olfson M, Gerhard T, Huang C, et al: Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72(12):1172–1181, 2015 26509694
Olfson M, Gerhard T, Crystal S, Stroup TS: Clozapine for schizophrenia: state variation in evidence-based practice. Psychiatr Serv 67(2):152, 2016 26522679
Olten B, Bloch MH: Meta regression: relationship between antipsychotic receptor binding profiles and side-effects. Prog Neuropsychopharmacol Biol Psychiatry 84 (Pt A):272–281, 2018 29410000
Oluwoye O, Monroe-DeVita M, Burduli E, et al: Impact of tobacco, alcohol and cannabis use on treatment outcomes among patients experiencing first episode psychosis: data from the national RAISE-ETP study. Early Interv Psychiatry 13(1):142–146, 2018
Ondo WG, Hanna PA, Jankovic J: Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 156(8):1279–1281, 1999 10450276
OnTrackNY: Resources. New York, OnTrackNY, 2019. Available at: https://ontrackny.org/Resources. Accessed March 31, 2019.
Opler MGA, Yavorsky C, Daniel DG: Positive and Negative Syndrome Scale (PANSS) training: challenges, solutions, and future directions. Innov Clin Neurosci 14(11–12):77–81, 2017 29410941
Opoka SM, Lincoln TM: The effect of cognitive behavioral interventions on depression and anxiety symptoms in patients with schizophrenia spectrum disorders: a systematic review. Psychiatr Clin North Am 40(4):641–659, 2017 29080591
Orap (pimozide) [prescribing information]. Sellersville, PA, Teva Pharmaceuticals, March 2014
Orap (pimozide) [prescribing information]. Horsham, PA, Teva Select Brands, April 2018
Orap (pimozide) [product monograph]. Vaughan, ON, Canada, AA Pharma, February 2019
Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, et al: Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev Jun 28 6(6):CD009005, 2017 28658515
Østergaard MLD, Nordentoft M, Hjorthøj C: Associations between substance use disorders and suicide or suicide attempts in people with mental illness: a Danish nation-wide, prospective, register-based study of patients diagnosed with schizophrenia, bipolar disorder, unipolar depression or personality disorder. Addiction 112(7):1250–1259, 2017 28192643
Østergaard SD, Foldager L, Mors O, et al: The validity and sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. Schizophr Bull 44(2):453–462, 2018a 28575321
Østergaard SD, Foldager L, Mors O, et al: The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Acta Psychiatr Scand 138(5):420–431, 2018b 30168131
Ostuzzi G, Bighelli I, So R, et al: Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res 183:10–21, 2017 27866695
Ouzzine M, Gulberti S, Ramalanjaona N, et al: The UDP-glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and detoxication. Front Cell Neurosci 8:349, 2014 25389387
Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 10:799–812, 1962
Ozbilen M, Adams CE: Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol 29(2):141–146, 2009 19512975
Pakzad-Vaezi KL, Etminan M, Mikelberg FS: The association between cataract surgery and atypical antipsychotic use: a nested case-control study. Am J Ophthalmol 156(6):1141–1146.e1, 2013 24075430
Palmer BA, Pankratz VS, Bostwick JM: The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 62(3):247–253, 2005 15753237
Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M: Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 69(5):759–768, 2008 18452342
Palmier-Claus JE, Ainsworth J, Machin M, et al: The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry 12:172, 2012
Pappa S, Tsouli S, Apostolou G, et al: Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 33(6):271–275, 2010 21121175
Paschen S, Deuschl G: Patient evaluation and selection for movement disorders surgery: the changing spectrum of indications. Prog Neurol Surg 33:80–93, 2018 29332075
Patel MM, Brown JD, Croake S, et al: The current state of behavioral health quality measures: where are the gaps? Psychiatr Serv 66(8):865–871, 2015
Patel MX, De Zoysa N, Bernadt M, David A: Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 23(7):789–796, 2009 18583438
Patel MX, de Zoysa N, Bernadt M, et al: Are depot antipsychotics more coercive than tablets? The patient’s perspective. J Psychopharmacol 24(10):1483–1489, 2010a 19304865
Patel MX, Haddad PM, Chaudhry IB, et al: Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 24(10):1473–1482, 2010b 19477883
Patterson-Lomba O, Ayyagari R, Carroll B: Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. BMC Neurol 19(1):174, 2019 31325958
PDSP: PDSP Ki database: Chapel Hill, NC, PDSP, 2019. Available at: https://pdsp.unc.edu/databases/kidb.php. Accessed January 16, 2019.
Pearsall R, Smith DJ, Pelosi A, Geddes J: Exercise therapy in adults with serious mental illness: a systematic review and meta-analysis. BMC Psychiatry 14:117, 2014 24751159
Pekkala E, Merinder L: Psychoeducation for schizophrenia. Cochrane Database Syst Rev (2):CD002831, 2002
Pelzer AC, van der Heijden FM, den Boer E: Systematic review of catatonia treatment. Neuropsychiatr Dis Treat 14:317–326, 2018 29398916
Pendopharm: Prpdp-benztropine prescribing information. Montreal, QC, Canada, Pendopharm, February 2, 2015. Available at: https://pdf.hres.ca/dpd_pm/00029138.PDF. Accessed April 22, 2019.
Pentaraki A, Utoblo B, Kokkoli EM: Cognitive remediation therapy plus standard care versus standard care for people with schizophrenia. Cochrane Database Syst Rev (11):CD012865, 2017
Penttilä M, Jääskeläinen E, Hirvonen N, et al: Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 205(2):88–94, 2014
Perphenazine [prescribing information]. Atlanta, GA, Wilshire Pharmaceuticals, November 2016
Perphenazine [prescribing information]. Morgantown, WV, Mylan Pharmaceuticals, March 2017
Perry BI, McIntosh G, Weich S, et al: The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis. Lancet Psychiatry 3(11):1049–1058, 2016 27720402
Perry LA, Ramson D, Stricklin S: Mirtazapine adjunct for people with schizophrenia. Cochrane Database Syst Rev May 26 5(5):CD011943, 2018 29802811
Perseris (risperidone) [prescribing information]. North Chesterfield, VA, Indivior, July 2018
Petrides G, Malur C, Braga RJ, et al: Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 172(1):52–58, 2015 25157964
Pharoah F, Mari J, Rathbone J, Wong W: Family intervention for schizophrenia. Cochrane Database Syst Rev Dec 8(12):CD000088, 2010 21154340
Phillips IR, Shephard EA: Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol 13(2):167–181, 2017 27678284
Pileggi DJ, Cook AM: Neuroleptic malignant syndrome. Ann Pharmacother 50(11):973–981, 2016 27423483
Pillinger T, Beck K, Gobjila C, et al: Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74(3):261–269, 2017a 28097367
Pillinger T, Beck K, Stubbs B, Howes OD: Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br J Psychiatry 211(6):339–349, 2017b 28982658
Pincus HA, Scholle SH, Spaeth-Rublee B, et al: Quality measures for mental health and substance use: gaps, opportunities, and challenges. Health Aff (Millwood) 35(6):1000–1008, 2016
Pinninti NR, Faden J, Adityanjee A: Are second-generation antipsychotics useful in tardive dystonia? Clin Neuropharmacol 38(5):183–197, 2015 26366970
Pisani F, Oteri G, Costa C, et al: Effects of psychotropic drugs on seizure threshold. Drug Saf 25(2):91–110, 2002 11888352
Pisciotta AV: Agranulocytosis induced by certain phenothiazine derivatives. JAMA 208(10):1862–1868, 1969 4890332
Plana-Ripoll O, Pedersen CB, Holtz Y, et al: Exploring comorbidity within mental disorders among a Danish national population. JAMA Psychiatry 76(3):259–270, 2019
Poewe W, Djamshidian-Tehrani A: Movement disorders in systemic diseases. Neurol Clin 33(1):269–297, 2015 25432733
Polcwiartek C, Vang T, Bruhn CH, et al: Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. Psychopharmacology (Berl) 233(21–22):3663–3672, 2016 27592232
Pompili M, Amador XF, Girardi P, et al: Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry 6:10, 2007
Pompili M, Lester D, Dominici G, et al: Indications for electroconvulsive treatment in schizophrenia: a systematic review. Schizophr Res 146(1-3):1–9, 2013 23499244
Popovic D, Benabarre A, Crespo JM, et al: Risk factors for suicide in schizophrenia: systematic review and clinical recommendations. Acta Psychiatr Scand 130(6):418–426, 2014 25230813
Pottegård A, Lash TL, Cronin-Fenton D, et al: Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study. Br J Clin Pharmacol 84(9):2152–2161, 2018 29858518
Poyurovsky M, Weizman A: Very low-dose mirtazapine (7.5 mg) in treatment of acute antipsychotic-associated akathisia. J Clin Psychopharmacol 38(6):609–611, 2018 30300293
Praharaj SK, Kongasseri S, Behere RV, Sharma PS: Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol 5(5):307–313, 2015 26557987
Predmore Z, Mattke S, Horvitz-Lennon M: Potential benefits to patients and payers from increased measurement of antipsychotic plasma levels in the management of schizophrenia. Psychiatr Serv 69(1):12–14, 2018 29191139
Preskorn S, Flynn A, Macaluso M: Determining whether a definitive causal relationship exists between aripiprazole and tardive dyskinesia and/or dystonia in patients with major depressive disorder, part 1. J Psychiatr Pract 21(5):359–369, 2015 26348804
Pringsheim T, Kelly M, Urness D, et al: Physical health and drug safety in individuals with schizophrenia. Can J Psychiatry 62(9):673–683, 2017
Pringsheim T, Gardner D, Addington D, et al: The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry Jan 1:706743718760288, 2018 Epub ahead of print
Procyshyn RM, Bezchlibnyk-Butler KZ, Jeffries JJ (eds): Clinical Handbook of Psychotropic Drugs, 23rd Edition. Boston, MA, Göttingen Hogrefe, 2019. Available at: https://chpd.hogrefe.com. Accessed January 4, 2019.
Pugh RN, Murray-Lyon IM, Dawson JL, et al: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8):646–649, 1973 4541913
Pui-yin Chung J, Shiu-yin Chong C, Lai-wah Dunn E, et al: The incidence and characteristics of clozapine-induced fever in a local psychiatric unit in Hong Kong. Can J Psychiatry 53(12):857–862, 2008 19087484
Pyne JM, Fischer EP, Gilmore L, et al: Development of a patient-centered antipsychotic medication adherence intervention. Health Educ Behav 41(3):315–324, 2014 24369177
Quetiapine (Seroquel) and QT-interval prolongation. Med Lett Drugs Ther 53(1374):79–80, 2011 21959358
Rabinowitz J, Levine SZ, Garibaldi G, et al: Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res 137(1–3):147–150, 2012
Ranasinghe I, Sin J: A systematic review of evidence-based treatment for individuals with treatment-resistant schizophrenia and a suboptimal response to clozapine monotherapy. Psychosis 6(3):253–265, 2014
Randall JR, Walld R, Finlayson G, et al: Acute risk of suicide and suicide attempts associated with recent diagnosis of mental disorders: a population-based, propensity score-matched analysis. Can J Psychiatry 59(10):531–538, 2014 25565686
Ratey JJ, Leveroni C, Kilmer D, et al: The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry 54(6):219–223, 1993 8331090
Rathbone J, Soares-Weiser K: Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev Oct 18(4):CD003727, 2006 17054182
Rautaharju PM, Surawicz B, Gettes LS, et al; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society: AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram, part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 53(11):982–991, 2009 19281931
Reagu S, Jones R, Kumari V, Taylor PJ: Angry affect and violence in the context of a psychotic illness: a systematic review and meta-analysis of the literature. Schizophr Res 146(1–3):46–52, 2013
Rebok GW, Ball K, Guey LT, et al; ACTIVE Study Group: Ten-year effects of the Advanced Cognitive Training for Independent and Vital Elderly cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc 62(1):16–24, 2014 24417410
Reeder C, Pile V, Crawford P, et al: The feasibility and acceptability to service users of CIRCuiTS, a computerized cognitive remediation therapy programme for schizophrenia. Behav Cogn Psychother 44(3):288–305, 2016 26004421
Reeder C, Huddy V, Cella M, et al: A new generation computerised metacognitive cognitive remediation programme for schizophrenia (CIRCuiTS): a randomised controlled trial. Psychol Med 1–11, 2017 28866988
Register-Brown K, Hong LE: Reliability and validity of methods for measuring the duration of untreated psychosis: a quantitative review and meta-analysis. Schizophr Res 160(1–3):20–26, 2014
Reingle Gonzalez JM, Connell NM: Mental health of prisoners: identifying barriers to mental health treatment and medication continuity. Am J Public Health 104(12):2328–2333, 2014 25322306
Relling MV, Klein TE: CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 89(3):464–467, 2011 21270786
Remington G, Agid O, Foussias G, et al: Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl) 225(3):505–518, 2013 23179967
Remington G, Addington D, Honer W, et al: Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry 62(9):604–616, 2017 28703015
Reser MP, Slikboer R, Rossell SL: A systematic review of factors that influence the efficacy of cognitive remediation therapy in schizophrenia. Aust N Z J Psychiatry 53(7):624–641, 2019 31177813
Revell ER, Neill JC, Harte M, et al: A systematic review and meta-analysis of cognitive remediation in early schizophrenia. Schizophr Res 168(1–2):213–222, 2015 26305063
Rexulti (brexpiprazole) [prescribing information]. Rockville, MD, Otsuka America Pharmaceutical, May 2019
Reynolds RJ, Day SM, Shafer A, Becker E: Mortality rates and excess death rates for the seriously mentally ill. J Insur Med 47(4):212–219, 2018 30653378
Rezansoff SN, Moniruzzaman A, Fazel S, et al: Housing first improves adherence to antipsychotic medication among formerly homeless adults with schizophrenia: results of a randomized controlled trial. Schizophr Bull 43(4):852–861, 2017 27665002
Richter D, Hoffmann H: Effectiveness of supported employment in non-trial routine implementation: systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol 54(5):525–531, 2019
Risperdal Consta (risperidone) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, January 2019
Risperdal (risperidone) [prescribing information]. Titusville, NJ, Janssen Pharmaceuticals, January 2019
Risperidone orally disintegrating tablets (risperidone) [prescribing information]. Princeton, NJ, Sandoz, February 2019
Roché MW, Boyle DJ, Cheng CC, et al: Prevalence and risk of violent ideation and behavior in serious mental illnesses: an analysis of 63,572 patient records. J Interpers Violence Mar 1: 886260518759976, 2018 Epub ahead of print
Røge R, Møller BK, Andersen CR, et al: Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res 140(1–3):204–213, 2012 22831769
Rogers HL, Bhattaram A, Zineh I, et al: CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration’s new dosing recommendations. J Clin Psychiatry 73(9):1187–1190, 2012 23059146
Rohde C, Polcwiartek C, Kragholm K, et al: Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study. Acta Psychiatr Scand 137(1):47–53, 2018 29064084
Ronaldson KJ, Fitzgerald PB, McNeil JJ: Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 132(4):231–240, 2015 25865238
Rosebush P, Stewart T: A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 146(6):717–725, 1989 2567121
Rosenheck RA, Davis S, Covell N, et al: Does switching to a new antipsychotic improve outcomes? Data from the CATIE trial. Schizophr Res 107(1):22–29, 2009 18993031
Rostack J: FDA to require diabetes warning on antipsychotics. Psychiatric News 30(20), Oct 17, 2003
Roth BL, Kroeze WK, Patel WK, Lopez E: The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrasment of riches? Neuroscientist 6(4):252–262, 2000
Rothe PH, Heres S, Leucht S: Dose equivalents for second generation long-acting injectable antipsychotics: the minimum effective dose method. Schizophr Res 193:23–28, 2018 28735640
Rouillon F, Eriksson L, Burba B, et al: Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Acta Neuropsychiatr 25(5):297–306, 2013 25287730
Rowland A, Miners JO, Mackenzie PI: The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 45(6):1121–1132, 2013 23500526
Roy L, Crocker AG, Nicholls TL, et al: Criminal behavior and victimization among homeless individuals with severe mental illness: a systematic review. Psychiatr Serv 65(6):739–750, 2014 24535245
Rubio-Abadal E, Del Cacho N, Saenz-Navarrete G, et al; PROLACT Group: How hyperprolactinemia affects sexual function in patients under antipsychotic treatment. J Clin Psychopharmacol 36(5):422–428, 2016 27433851
Rush AJ, First MB, Blacker D (eds): Handbook of Psychiatric Measures, 2nd Edition. Washington, DC, American Psychiatric Publishing, 2008
Sachdev P, Mason C, Hadzi-Pavlovic D: Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 154(8):1156–1158, 1997 9247408
Sachs HC; Committee on Drugs: The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics 132(3):e796–e809, 2013 23979084
Saha S, Chant D, McGrath J: A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64(10):1123–1131, 2007
Saklad SR: Paliperidone palmitate: adjusting dosing intervals and measuring serum concentrations. Curr Psychiatr 17(8):45–47, 55, 2018
Saks ER: Some thoughts on denial of mental illness. Am J Psychiatry 166(9):972–973, 2009 19723794
Salahudeen MS, Duffull SB, Nishtala PS: Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr 15:31, 2015 25879993
Saltz BL, Woerner MG, Kane JM, et al: Prospective study of tardive dyskinesia incidence in the elderly. JAMA 266(17):2402–2406, 1991 1681122
Samara M, Leucht S: Clozapine in treatment-resistant schizophrenia. Br J Psychiatry 210(4):299, 2017 28373226
Samara MT, Leucht C, Leeflang MM, et al: Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172(7):617–629, 2015 26046338
Samara MT, Dold M, Gianatsi M, et al: Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry 73(3):199–210, 2016 26842482
Samara MT, Klupp E, Helfer B, et al: Increasing antipsychotic dose for non response in schizophrenia. Cochrane Database Syst Rev May 11 5(5):CD0011883, 2018 29750432
SAMHSA-HRSA Center of Excellence for Integrated Health Solutions: Tobacco cessation. Rockville, MD, SAMHSA-HRSA Center for Integrated Health Solutions, 2018. Available at: www.integration.samhsa.gov/health-wellness/wellness-strategies/tobacco-cessation-2. Accessed December 31, 2018.
SAMHSA-HRSA Center of Excellence for Integrated Health Solutions: SBIRT: Screening, brief intervention, and referral to treatment. Rockville, MD, SAMHSA-HRSA Center for Integrated Health Solutions, 2019. Available at: www.integration.samhsa.gov/clinical-practice/sbirt. Accessed September 22, 2019.
Santesteban-Echarri O, Paino M, Rice S, et al: Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. Clin Psychol Rev 58:59–75, 2017 29042139
Saperstein AM, Medalia A: The empirical basis for the practice of cognitive remediation for schizophrenia. Neuropsychiatry (London) 2(2):101–109, 2012
Saphris (asenapine) [prescribing information]. Irvine, CA, Allergan USA, February 2017
Sara GE, Burgess PM, Malhi GS, et al: Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample. Aust N Z J Psychiatry 48(11):1036–1047, 2014 24819935
Sariaslan A, Lichtenstein P, Larsson H, Fazel S: Triggers for violent criminality in patients with psychotic disorders. JAMA Psychiatry 73(8):796–803, 2016 27410165
Satterthwaite TD, Wolf DH, Rosenheck RA, et al: A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 69(12):1869–1879, 2008 19192477
Schalinski I, Breinlinger S, Hirt V, et al: Environmental adversities and psychotic symptoms: the impact of timing of trauma, abuse, and neglect. Schizophr Res 205:4–9, 2019
Scherf-Clavel M, Samanski L, Hommers LG, et al: Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2. Int Clin Psychopharmacol 34(2):93–100, 2019
Schneider M, Regente J, Greiner T, et al: Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993–2015. Eur Arch Psychiatry Clin Neurosci Nov 30, 2018 Epub ahead of print
Schoenbaum M, Sutherland JM, Chappel A, et al: Twelve-month health care use and mortality in commercially insured young people with incident psychosis in the United States. Schizophr Bull 43(6):1262–1272, 2017 28398566
Schwartz RC, Blankenship DM: Racial disparities in psychotic disorder diagnosis: a review of empirical literature. World J Psychiatry 4(4):133–140, 2014 25540728
Scott D, Platania-Phung C, Happell B: Quality of care for cardiovascular disease and diabetes amongst individuals with serious mental illness and those using antipsychotic medications. J Healthc Qual 34(5):15–21, 2012 22092725
Scottish Intercollegiate Guidelines Network (SIGN): Management of schizophrenia. Edinburgh, SIGN, May 2013. Available at: www.sign.ac.uk/assets/sign131.pdf. Accessed April 26, 2019.
Secher RG, Hjorthøj CR, Austin SF, et al: Ten-year follow-up of the OPUS specialized early intervention trial for patients with a first episode of psychosis. Schizophr Bull 41(3):617–626, 2015 25381449
Segal SP, Hayes SL, Rimes L: The utility of outpatient commitment I: a need for treatment and a least restrictive alternative to psychiatric hospitalization. Psychiatr Serv 68(12):1247–1254, 2017a Epub Aug 1 2017 28760100
Segal SP, Hayes SL, Rimes L: The utility of outpatient commitment II: mortality risk and protecting health, safety, and quality of life. Psychiatr Serv 68(12):1255–1261, 2017b 28760099
Sellwood W, Barrowclough C, Tarrier N, et al: Needs-based cognitive-behavioural family intervention for carers of patients suffering from schizophrenia: 12-month follow-up. Acta Psychiatr Scand 104(5):346–355, 2001 11722315
Sellwood W, Wittkowski A, Tarrier N, Barrowclough C: Needs-based cognitive-behavioural family intervention for patients suffering from schizophrenia: 5-year follow-up of a randomized controlled effectiveness trial. Acta Psychiatr Scand 116(6):447–452, 2007 17961200
Semenza DC, Grosholz JM: Mental and physical health in prison: how co-occurring conditions influence inmate misconduct. Health Justice 7(1):1, 2019 30612284
Seroquel (quetiapine) [prescribing information]. Wilmington, DE, AstraZeneca Pharmaceuticals, August 2019
Seroquel XR (quetiapine) [prescribing information]. Wilmington, DE, AstraZeneca Pharmaceuticals, August 2019
Serretti A, Chiesa A: A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 26(3):130–140, 2011 21191308
Shafrin J, Schwartz TT, Lakdawalla DN, Forma FM: Estimating the value of new technologies that provide more accurate drug adherence information to providers for their patients with schizophrenia. J Manag Care Spec Pharm 22(11):1285–1291, 2016 27783545
Sharma R, Alla K, Pfeffer D, et al: An appraisal of practice guidelines for smoking cessation in people with severe mental illness. Aust N Z J Psychiatry 51(11):1106–1120, 2017 28859486
Shen V, Clarence-Smith K, Hunter C, Jankovic J: Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington’s and other diseases. Tremor Other Hyperkinet Mov (N Y) 3:tre-03-191-4337-1, 2013 24255799
Shen WK, Sheldon RS, Benditt DG, et al: 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 70(5):e39–e110, 2017 28286221
Sherman LJ, Lynch SE, Teich J, Hudock WJ: Availability of supported employment in specialty mental health treatment facilities and facility characteristics: 2014. The CBHSQ Report. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2017 28749638
Shields LS, Pathare S, van der Ham AJ, Bunders J: A review of barriers to using psychiatric advance directives in clinical practice. Adm Policy Ment Health 41(6):753–766, 2014 24248818
Short T, Thomas S, Mullen P, Ogloff JR: Comparing violence in schizophrenia patients with and without comorbid substance-use disorders to community controls. Acta Psychiatr Scand 128(4):306–313, 2013
Siegel M, Rothman EF: Firearm ownership and suicide rates among US men and women, 1981–2013. Am J Public Health 106(7):1316–1322, 2016 27196643
Silberstein J, Harvey PD: Impaired introspective accuracy in schizophrenia: an independent predictor of functional outcomes. Cogn Neuropsychiatry 24(1):28–39, 2019 30477401
Silver H, Geraisy N, Schwartz M: No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 56(4):167–170, 1995 7713856
Sin J, Gillard S, Spain D, et al: Effectiveness of psychoeducational interventions for family carers of people with psychosis: a systematic review and meta-analysis. Clin Psychol Rev 56:13–24, 2017a 28578249
Sin J, Spain D, Furuta M, et al: Psychological interventions for post-traumatic stress disorder (PTSD) in people with severe mental illness. Cochrane Database Syst Rev Jan 24 1(1):CD011464, 2017b 28116752
Sinclair D, Adams CE: Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatry 14:253, 2014 25227719
Sinclair DJ, Zhao S, Qi F, et al: Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev Mar 19 3(3):CD011847, 2019 30888709
Singh JP, Grann M, Lichtenstein P, et al: A novel approach to determining violence risk in schizophrenia: developing a stepped strategy in 13,806 discharged patients. PLoS One 7(2):e31727, 2012 22359622
Singh ML, Papas A: Oral implications of polypharmacy in the elderly. Dent Clin North Am 58(4):783–796, 2014 25201542
Siskind DJ, Leung J, Russell AW, et al: Metformin for clozapine associated obesity: a systematic review and meta-analysis. PLoS One 11(6):e0156208, 2016a 27304831
Siskind D, McCartney L, Goldschlager R, Kisely S: Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 209(5):385–392, 2016b 27388573
Siskind DJ, Harris M, Phillipou A, et al: Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis. Epidemiol Psychiatr Sci 26(3):325–337, 2017a 27426892
Siskind D, Siskind V, Kisely S: Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry 62(11):772–777, 2017b 28655284
Siskind DJ, Lee M, Ravindran A, et al: Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry 52(8):751–767, 2018 29732913
Siskind D, Hahn M, Correll CU, et al: Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab 21(2):293–302, 2019 30187620
Siu AL; U.S. Preventive Services Task Force: Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 163(8):622–634, 2015 26389730
Skevington SM, Lotfy M, O’Connell KA; WHOQOL Group: The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL Group. Qual Life Res 13(2):299–310, 2004
SMI Adviser: How do I establish tolerability before starting a long acting injectable antipsychotic medication (LAI), and how do I ensure the patient will not have side effects? Washington, DC, American Psychiatric Association, September 4, 2019. Available at: https://smiadviser.org/knowledge_post/how-do-i-establishing-tolerability-before-starting-a-long-acting-injectable-antipsychotic-medication-lai-and-how-do-i-ensure-the-patient-will-not-have-side-effects. Accessed October 9, 2019.
Smith FA, Levenson JL, Stern TA: Psychiatric assessment and consultation, in The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psychiatry, 3rd Edition. Edited by Levenson JL. Washington, DC, American Psychiatric Association Publishing, 2019, pp 3–24
Smith PH, Mazure CM, McKee SA: Smoking and mental illness in the U.S. population. Tob Control 23(e2):e147–e153, 2014 24727731
Soares-Weiser K, Rathbone J: Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev (11):CD000206, 2011 14973950
Soares-Weiser K, Maayan N, Bergman H: Vitamin E for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev Jan 17 1(1):CD000209, 2018a 29341067
Soares-Weiser K, Rathbone J, Ogawa Y, et al: Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev Mar 19 3(3):CD000208, 2018b 29552749
Solmi M, Pigato G, Kane JM, Correll CU: Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci 389:21–27, 2018a 29439776
Solmi M, Pigato G, Kane JM, Correll CU: Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 12:1215–1238, 2018b 29795977
Solmi M, Fornaro M, Toyoshima K, et al: Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. CNS Spectr 24(5):479–495, 2019 30460884
Sood S, James W, Bailon MJ: Priapism associated with atypical antipsychotic medications: a review. Int Clin Psychopharmacol 23(1):9–17, 2008 18090503
Souza JS, Kayo M, Tassell I, et al: Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr 18(2):82–89, 2013 23253621
Sparshatt A, Taylor D, Patel MX, Kapur S: A systematic review of aripiprazole: dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 71(11):1447–1456, 2010 20584524
Spina E, Sturiale V, Valvo S, et al: Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. Int Clin Psychopharmacol 8(1):21–24, 1993 8097213
Spina E, Avenoso A, Facciolà G, et al: Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 148(1):83–89, 2000 10663421
Spitz A, Studerus E, Koranyi S, et al: Correlations between self-rating and observer-rating of psychopathology in at-risk mental state and first-episode psychosis patients: influence of disease stage and gender. Early Interv Psychiatry 11(6):461–470, 2017 26376725
Stanilla JK, Simpson GM: Drugs to treat extrapyramidal side effects, in The American Psychiatric Association Publishing Textbook of Psychopharmacology, 5th Edition. Edited by Schatzberg AF, Nemeroff CB. Arlington, VA, American Psychiatric Association Publishing, 2017, pp 855–885
Stanley B, Brown GK: Safety planning intervention: a brief intervention to mitigate suicide risk. Cognit Behav Pract 19(2):256–264, 2012
Stanley B, Brown GK: About safety planning. Safety Planning Intervention 2019. Available at: http://suicide safetyplan.com/About_Safety_Planning.html. Accessed December 28, 2018.
Stanley B, Brown GK, Brenner LA, et al: Comparison of the safety planning intervention with follow-up vs usual care of suicidal patients treated in the emergency department. JAMA Psychiatry 75(9):894–900, 2018 29998307
Stanton AH, Gunderson JG, Knapp PH, et al: Effects of psychotherapy in schizophrenia I: design and implementation of a controlled study. Schizophr Bull 10(4):520–563, 1984 6151245
Stark A, Scott J: A review of the use of clozapine levels to guide treatment and determine cause of death. Aust N Z J Psychiatry 46(9):816–825, 2012 22327098
Steadman HJ, Osher FC, Robbins PC, et al: Prevalence of serious mental illness among jail inmates. Psychiatr Serv 60(6):761–765, 2009 19487344
Stirman SW, Spokas M, Creed TA, et al: Training and consultation in evidence-based psychosocial treatments in public mental health settings: the ACCESS model. Prof Psychol Res Pr 41(1):48–56, 2010 22872783
Stoecker ZR, George WT, O’Brien JB, et al: Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. Int Clin Psychopharmacol 32(3):155–160, 2017 28059928
Strawn JR, Keck PE Jr, Caroff SN: Neuroleptic malignant syndrome. Am J Psychiatry 164(6):870–876, 2007 17541044
Streck JM, Weinberger AH, Pacek LR, et al: Cigarette smoking quit rates among persons with serious psychological distress in the United States from 2008 to 2016: are mental health disparities in cigarette use increasing? Nicotine Tob Res 22(1):130–134, 2020
Stringhini S, Carmeli C, Jokela M, et al; LIFEPATH consortium: Socioeconomic status and the 25×25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1·7 million men and women. Lancet 389(10075):1229–1237, 2017 28159391
Stroup TS, Lieberman JA, McEvoy JP, et al; CATIE Investigators: Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 164(3):415–427, 2007 17329466
Stroup TS, Lieberman JA, McEvoy JP, et al; CATIE Investigators: Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 107(1):1–12, 2009 19027269
Stroup TS, McEvoy JP, Ring KD, et al; Schizophrenia Trials Network: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168(9):947–956, 2011 21768610
Stroup TS, Byerly MJ, Nasrallah HA, et al: Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res 146(1–3):190–195, 2013 23434503
Stroup TS, Gerhard T, Crystal S, et al: Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv 65(2):186–192, 2014 24233347
Stroup TS, Gerhard T, Crystal S, et al: Comparative effectiveness of adjunctive psychotropic medications in patients with schizophrenia. JAMA Psychiatry 76(5):508–515, 2019
Strub RL, Black FW: The Mental Status Examination in Neurology. Philadelphia, PA, FA Davis, 2000
Stubbs B, De Hert M, Sepehry AA, et al: A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand 130(6):470–486, 2014 25041606
Stubbs B, Gaughran F, Mitchell AJ, et al: Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry 37(2):126–133, 2015 25666994
Stubbs B, Firth J, Berry A, et al: How much physical activity do people with schizophrenia engage in? A systematic review, comparative meta-analysis and meta-regression. Schizophr Res 176(2-3):431–440, 2016a 27261419
Stubbs B, Vancampfort D, Veronese N, et al: The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: a systematic review and meta-analysis. J Affect Disord 197:259–267, 2016b
Stübner S, Rustenbeck E, Grohmann R, et al: Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 37 (suppl 1):S54–S64, 2004 15052515
Subotnik KL, Casaus LR, Ventura J, et al: Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry 72(8):822–829, 2015
Substance Abuse and Mental Health Services Administration: Assertive Community Treatment (ACT) Evidence-Based Practices (EBP) KIT. Rockville, MD, Substance Abuse and Mental Health Services Administration, October 2008. Available at: https://store.samhsa.gov/product/Assertive-Community-Treatment-ACT-Evidence-Based-Practices-EBP-KIT/sma08-4345. Accessed March 31, 2019.
Substance Abuse and Mental Health Services Administration: Family Psychoeducation Evidence-Based Practices (EBP) KIT (HHS Publ No SMA-09-4422). Rockville, MD, Substance Abuse and Mental Health Services Administration, 2009. Available at: https://store.samhsa.gov/product/Family-Psychoeducation-Evidence-Based-Practices-EBP-KIT/sma09-4422. Accessed October 1, 2019.
Substance Abuse and Mental Health Services Administration: Illness Management and Recovery Evidence-Based Practices (EBP) KIT. Rockville, MD, Substance Abuse and Mental Health Services Administration, March 2010a. Available at: https://store.samhsa.gov/product/Illness-Management-and-Recovery-Evidence-Based-Practices-EBP-KIT/sma09-4463. Accessed April 6, 2019.
Substance Abuse and Mental Health Services Administration: Supported Employment Evidence-Based Practices (EBP) KIT. Rockville, MD, Substance Abuse and Mental Health Services Administration, February 2010b. Available at: https://store.samhsa.gov/product/Supported-Employment-Evidence-Based-Practices-EBP-Kit/SMA08-4364. Accessed July 24, 2020.
Substance Abuse and Mental Health Services Administration: SAMHSA’s working definition of recovery: 10 guiding principles of recovery. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2012a. Available at: https://store.samhsa.gov/system/files/pep12-recdef.pdf. Accessed August 3, 2019.
Substance Abuse and Mental Health Services Administration: Supported Education Evidence-Based Practices (EBP) KIT. Rockville, MD, Substance Abuse and Mental Health Services Administration, August 2012b. Available at: https://store.samhsa.gov/product/Supported-Education-Evidence-Based-Practices-EBP-KIT/SMA11-4654CD-ROM. Accessed August 19, 2019.
Suijkerbuijk YB, Schaafsma FG, van Mechelen JC, et al: Interventions for obtaining and maintaining employment in adults with severe mental illness, a network meta-analysis. Cochrane Database Syst Rev Sep 12 9(9):CD011867, 2017 28898402
Sultana J, Hurtado I, Bejarano-Quisoboni D, et al: Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. Eur J Clin Pharmacol 75(7):1005–1015, 2019 30824947
Susman VL, Addonizio G: Recurrence of neuroleptic malignant syndrome. J Nerv Ment Dis 176(4):234–241, 1988 2895164
Suzuki T, Uchida H, Watanabe K, Kashima H: Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol Bull 44(1):32–60, 2011 22506438
Swanson CL, Trestman RL: Rural assertive community treatment and telepsychiatry. J Psychiatr Pract 24(4):269–273, 2018 30427810
Swanson JW, Swartz MS, Van Dorn RA, et al: A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry 63(5):490–499, 2006 16651506
Swanson SJ, Becker DR, Bond GR: Job development guidelines in supported employment. Psychiatr Rehabil J 36(2):122–123, 2013 23750766
Swartz MS, Wagner HR, Swanson JW, et al: Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 194(3):164–172, 2006 16534433
Swartz MS, Bhattacharya S, Robertson AG, Swanson JW: Involuntary outpatient commitment and the elusive pursuit of violence prevention. Can J Psychiatry 62(2):102–108, 2017 27777274
Swillen A, McDonald-McGinn D: Developmental trajectories in 22q11.2 deletion. Am J Med Genet C Semin Med Genet 169(2):172–181, 2015 25989227
Sytema S, Wunderink L, Bloemers W, et al: Assertive community treatment in the Netherlands: a randomized controlled trial. Acta Psychiatr Scand 116(2):105–112, 2007 17650271
Taipale H, Mehtälä J, Tanskanen A, Tiihonen J: Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia: a nationwide study with 20-year follow-up. Schizophr Bull 44(6):1381–1387, 2018a 29272458
Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al: Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res 197:274–280, 2018b 29274734
Takeuchi H, Powell V, Geisler S, et al: Clozapine administration in clinical practice: once-daily versus divided dosing. Acta Psychiatr Scand 134(3):234–240, 2016 27182769
Takeuchi H, Kantor N, Uchida H, et al: Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. Schizophr Bull 43(4):862–871, 2017a 28044008
Takeuchi H, Thiyanavadivel S, Agid O, Remington G: Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: a meta-analysis. Schizophr Res 189:4–8, 2017b 28242107
Takeuchi H, Siu C, Remington G, et al: Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology 44(6):1036–1042, 2019 30514883
Tam J, Warner KE, Meza R: Smoking and the reduced life expectancy of individuals with serious mental illness. Am J Prev Med 51(6):958–966, 2016 27522471
Tamburello A, Metzner J, Fergusen E, et al: The American Academy of Psychiatry and the Law practice resource for prescribing in corrections. J Am Acad Psychiatry Law 46(2):242–243, 2018 30026404
Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H: Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev Mar 19 3(3):CD000207, 2018 29553158
Tang Y, Horvitz-Lennon M, Gellad WF, et al: Prescribing of clozapine and antipsychotic polypharmacy for schizophrenia in a large Medicaid program. Psychiatr Serv 68(6):579–586, 2017 28196460
Tanskanen A, Tiihonen J, Taipale H: Mortality in schizophrenia: 30-year nationwide follow-up study. Acta Psychiatr Scand 138(6):492-499, 2018 29900527
Tarsy D, Baldessarini RJ: Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 21(5):589–598, 2006 16532448
Tauber R, Wallace CJ, Lecomte T: Enlisting indigenous community supporters in skills training programs for persons with severe mental illness. Psychiatr Serv 51(11):1428–1432, 2000 11058191
Teasdale SB, Samaras K, Wade T, et al: A review of the nutritional challenges experienced by people living with severe mental illness: a role for dietitians in addressing physical health gaps. J Hum Nutr Diet 30(5):545–553, 2017 28419586
Thioridazine hydrochloride [prescribing information]. Morgantown, WV, Mylan Pharmaceuticals, November 2016
Thomas EC, Despeaux KE, Drapalski AL, Bennett M: Person-oriented recovery of individuals with serious mental illnesses: a review and meta-analysis of longitudinal findings. Psychiatr Serv 69(3):259–267, 2018
Thompson A, Winsper C, Marwaha S, et al: Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review. BJPsych Open 4(4):215–225, 2018 29988997
Thorning H, Marino L, Jean-Noel P, et al: Adoption of a blended training curriculum for ACT in New York State. Psychiatr Serv 67(9):940–942, 2016 27181739
Tiihonen J, Haukka J, Taylor M, et al: A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168(6):603–609, 2011 21362741
Tiihonen J, Mittendorfer-Rutz E, Torniainen M, et al: Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 173(6):600–606, 2016 26651392
Tiihonen J, Mittendorfer-Rutz E, Majak M, et al: Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry 74(7):686–693, 2017 28593216
Tiihonen J, Tanskanen A, Taipale H: 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 75(8):765–773, 2018 29621900
Tiihonen J, Taipale H, Mehtälä J, et al: Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 76(5):499–507, 2019
Toftdahl NG, Nordentoft M, Hjorthøj C: Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study. Soc Psychiatry Psychiatr Epidemiol 51(1):129–140, 2016 26260950
Toohey MJ, Muralidharan A, Medoff D, et al: Caregiver positive and negative appraisals: effects of the National Alliance on Mental Illness Family-to-Family intervention. J Nerv Ment Dis 204(2):156–159, 2016 26825266
Tosato S, Albert U, Tomassi S, et al: A systematized review of atypical antipsychotics in pregnant women: balancing between risks of untreated illness and risks of drug-related adverse effects. J Clin Psychiatry 78(5):e477–e489, 2017 28297592
Trifluoperazine [prescribing information]. Princeton, NJ, Sandoz, October 2017
Trihexyphenidyl hydrochloride oral solution [prescribing information]. Greenville, SC, Pai Pharmaceutical Associates, October 2010
Trihexyphenidyl hydrochloride tablets [prescribing information]. Buffalo Grove, IL, Pack Pharmaceuticals, June 2015
Trotta A, Murray RM, Fisher HL: The impact of childhood adversity on the persistence of psychotic symptoms: a systematic review and meta-analysis. Psychol Med 45(12):2481–2498, 2015 25903153
Tseng PT, Chen YW, Yeh PY, et al: Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA. Medicine (Baltimore), 94(47):e1967, 2015 26632691
Tsuboi T, Bies RR, Suzuki T, et al: Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Prog Neuropsychopharmacol Biol Psychiatry 45:178–182, 2013 23727135
Turkington D, Spencer HM: Back to Life, Back to Normality, Vol 2: CBT Informed Recovery for Families With Relatives With Schizophrenia and Other Psychosis. Cambridge, UK, Cambridge University Press, 2019
Turkington D, Kingdon D, Weiden PJ: Cognitive behavior therapy for schizophrenia. Am J Psychiatry 163(3):365–373, 2006 16513854
Turner DT, McGlanaghy E, Cuijpers P, et al: A meta-analysis of social skills training and related interventions for psychosis. Schizophr Bull 44(3):475–491, 2018 29140460
Twamley EW, Vella L, Burton CZ, et al: Compensatory cognitive training for psychosis: effects in a randomized controlled trial. J Clin Psychiatry 73(9):1212–1219, 2012 22939029
Uchida H, Suzuki T, Takeuchi H, et al: Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull 37(4):788–799, 2011a 19946012
Uchida H, Takeuchi H, Graff-Guerrero A, et al: Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol 31(3):318–325, 2011b 21508857
Unal A, Altindag A, Demir B, Aksoy I: The use of lorazepam and electroconvulsive therapy in the treatment of catatonia: treatment characteristics and outcomes in 60 patients. J ECT 33(4):290–293, 2017 28640169
Unützer J, Katon W, Callahan CM, et al; IMPACT Investigators. Improving Mood-Promoting Access to Collaborative Treatment: Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 288(22):2836–2845, 2002
U.S. Department of Health and Human Services: The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA, Centers for Disease Control and Prevention, 2014. Available at: www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/index.htm. Accessed December 29, 2018.
U.S. Department of Health and Human Services; U.S. National Library of Medicine: Chlorpromazine, in LiverTox. U.S. Department of Health and Human Services, October 5, 2017a. Available at: www.ncbi.nlm.nih.gov/books/NBK548793. Accessed May 6, 2020.
U.S. Department of Health and Human Services; U.S. National Library of Medicine: Antipsychotic agents. Washington, DC, U.S. Department of Health and Human Services, July 20, 2017b. Available at: www.ncbi.nlm.nih.gov/books/NBK548317. Accessed May 6, 2020.
U.S. Food and Drug Administration: Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Silver Spring, MD, U.S. Food and Drug Administration, May 2003. Available at: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm072123.pdf. Accessed May 8, 2019.
U.S. Food and Drug Administration: FDA drug safety communication: antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. Silver Spring, MD, U.S. Food and Drug Administration, February 22, 2011a. Available at: www.fda.gov/Drugs/DrugSafety/ucm243903.htm#sa. Accessed September 22, 2019.
U.S. Food and Drug Administration: Center for Drug Evaluation and Research approval package for Orap (pimozide), NDA 17-473/S046. Silver Spring, MD, U.S. Food and Drug Administration, September 27, 2011b. Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2011/017473Orig1s046.pdf. Accessed on February 1, 2019.
U.S. Food and Drug Administration: FDA approves pill with sensor that digitally tracks if patients have ingested their medication. Silver Spring, MD, U.S. Food and Drug Administration, November 13, 2017. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584933.htm. Accessed February 1, 2019.
U.S. Food and Drug Administration: Table of pharmacogenomic biomarkers in drug labeling. Silver Spring, MD, U.S. Food and Drug Administration, 2019. Available at: www.fda.gov/drugs/science-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling. Accessed August 11, 2019.
U.S. National Library of Medicine: Daily Med: pimozide tablet. Bethesda, MD, National Institutes of Health, May 2018a. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280. Accessed May 7, 2020.
U.S. National Library of Medicine: Daily Med. Thioridazine Hydrochloride. Bethesda, MD, National Institutes of Health, December 21, 2018b. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm? setid=52fea941-0b47-41c1-b00d-f88150e8ab93#boxedwarning. Accessed February 8, 2019.
Üstün TB, Kostanjsek N, Chatterji S, Rehm J: Measuring Health and Disability: Manual for WHO Disability Assessment Schedule (WHODAS 2.0). Geneva, Switzerland, World Health Organization, 2010
Valencia M, Rascon ML, Juarez F, Murow E: A psychosocial skills training approach in Mexican out-patients with schizophrenia. Psychol Med 37(10):1393–1402, 2007 17472761
Valencia M, Fresan A, Juárez F, et al: The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia. J Psychiatr Res 47(12):1886–1892, 2013 24112947
Valenstein M, Ganoczy D, McCarthy JF, et al: Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 67(10):1542–1550, 2006 17107245
Valenstein M, Adler DA, Berlant J, et al: Implementing standardized assessments in clinical care: now’s the time. Psychiatr Serv 60(10):1372–1375, 2009
Valmaggia LR, Tabraham P, Morris E, Bouman TK: Cognitive behavioral therapy across the stages of psychosis: prodromal, first episode, and chronic schizophrenia. Cogn Behav Pract 15(2):179–193, 2008
Van L, Boot E, Bassett AS: Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia. Curr Opin Psychiatry 30(3):191–196, 2017 28230630
Vancampfort D, Stubbs B, Mitchell AJ, et al: Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 14(3):339–347, 2015
Vancampfort D, Correll CU, Galling B, et al: Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 15(2):166–174, 2016a
Vancampfort D, Rosenbaum S, Schuch FB, et al: Prevalence and predictors of treatment dropout from physical activity interventions in schizophrenia: a meta-analysis. Gen Hosp Psychiatry 39:15–23, 2016b 26719106
Vancampfort D, Rosenbaum S, Schuch F, et al: Cardiorespiratory fitness in severe mental illness: a systematic review and meta-analysis. Sports Med 47(2):343–352, 2017 27299747
Vancampfort D, Firth J, Correll CU, et al: The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry 18(1):53–66, 2019 30600626
Van Citters AD, Pratt SI, Jue K, et al: A pilot evaluation of the In SHAPE individualized health promotion intervention for adults with mental illness. Community Ment Health J 46(6):540–552, 2010 20012197
Vandenberk B, Vandael E, Robyns T, et al: Which QT correction formulae to use for QT monitoring? J Am Heart Assoc 5(6):e003264, 2016 27317349
van der Gaag M, Stant AD, Wolters KJ, et al: Cognitive-behavioural therapy for persistent and recurrent psychosis in people with schizophrenia-spectrum disorder: cost-effectiveness analysis. Br J Psychiatry 198(1):59–65, 2011
Vanderlip ER, Henwood BF, Hrouda DR, et al: Systematic literature review of general health care interventions within programs of assertive community treatment. Psychiatr Serv 68(3):218–224, 2017 27903142
van der Werf M, Hanssen M, Köhler S, et al: Systematic review and collaborative recalculation of 133,693 incident cases of schizophrenia. Psychol Med 44(1):9–16, 2014 23244442
VanderZwaag C, McGee M, McEvoy JP, et al: Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 153(12):1579–1584, 1996 8942454
van Dijk F, de Wit I, Blankers M, et al: The Personal Antipsychotic Choice Index. Pharmacopsychiatry 51(3):89–99, 2018 28810270
van Duin D, de Winter L, Oud M, et al: The effect of rehabilitation combined with cognitive remediation on functioning in persons with severe mental illness: systematic review and meta-analysis. Psychol Med 49(9):1414–1425, 2019 30696500
van Dulmen SA, Lukersmith S, Muxlow J, et al; G-I-N Allied Health Steering Group: Supporting a person-centred approach in clinical guidelines: a position paper of the Allied Health Community—Guidelines International Network (G-I-N). Health Expect 18(5):1543–1558, 2015 24118821
van Harten PN, Hoek HW, Kahn RS: Acute dystonia induced by drug treatment. BMJ 319(7210):623–626, 1999 10473482
Van Putten T, Aravagiri M, Marder SR, et al: Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients. Psychopharmacol Bull 27(2):91–96, 1991 1924666
Van Schayck OCP, Williams S, Barchilon V, et al: Treating tobacco dependence: guidance for primary care on life-saving interventions. Position statement of the IPCRG. NPJ Prim Care Respir Med 27(1):38, 2017 28600490
van Strien AM, Keijsers CJ, Derijks HJ, van Marum RJ: Rating scales to measure side effects of antipsychotic medication: a systematic review. J Psychopharmacol 29(8):857–866, 2015 26156860
Varese F, Smeets F, Drukker M, et al: Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull 38(4):661–671, 2012 22461484
Vaucher J, Keating BJ, Lasserre AM, et al: Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry 23(5):1287–1292, 2018 28115737
Veerman SR, Schulte PF, Begemann MJ, de Haan L: Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Pharmacopsychiatry 47(7):231–238, 2014 25121994
Velligan DI, Lam YW, Glahn DC, et al: Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 32(4):724–742, 2006 16707778
Velligan DI, Weiden PJ, Sajatovic M, et al; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness: The Expert Consensus Guideline Series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70 (suppl 4):1–46, 2009 19686636
Velligan DI, Weiden PJ, Sajatovic M, et al: Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 16(5):306–324, 2010 20859108
Velligan DI, Medellin E, Draper M, et al: Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center. Community Ment Health J 47(6):654–659, 2011 21253830
Velligan DI, Sajatovic M, Hatch A, et al: Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence 11:449–468, 2017 28424542
Velthorst E, Koeter M, van der Gaag M, et al: Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. Psychol Med 45(3):453–465, 2015 24993642
Ventura J, Green MF, Shaner A, Liberman RP: Training and quality assurance in the use of the Brief Psychiatric Rating Scale: the “drift busters.” Int J Methods Psychiatr Res 3:221–244, 1993
Verbiest M, Brakema E, van der Kleij R, et al: National guidelines for smoking cessation in primary care: a literature review and evidence analysis. NPJ Prim Care Respir Med 27(1):2, 2017 28108747
Verdoux H, Quiles C, Bachmann CJ, Siskind D: Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophr Res 201:10–19, 2018 29880453
Verhaeghe N, Clays E, Vereecken C, et al: Health promotion in individuals with mental disorders: a cluster preference randomized controlled trial. BMC Public Health 13:657, 2013 23855449
Vermeir M, Naessens I, Remmerie B, et al: Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 36(4):769–779, 2008 18227146
Vermeulen J, van Rooijen G, Doedens P, et al: Antipsychotic medication and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis. Psychol Med 47(13):2217–2228, 2017 28397632
Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, et al: Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophr Bull 45(2):315–329, 2019 29697804
Victoroff J, Coburn K, Reeve A, et al: Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review. J Neuropsychiatry Clin Neurosci 26(4):283–312, 2014 26037853.
Viejo LF, Morales V, Puñal P, et al: Risk factors in neuroleptic malignant syndrome: a case-control study. Acta Psychiatr Scand 107(1):45–49, 2003 12558541
Viertiö S, Laitinen A, Perälä J, et al: Visual impairment in persons with psychotic disorder. Soc Psychiatry Psychiatr Epidemiol 42(11):902–908, 2007 17846698
Vinogradov S, Fisher M, Warm H, et al: The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 166(9):1055–1062, 2009 19570929
Vita A, De Peri L, Barlati S, et al: Effectiveness of different modalities of cognitive remediation on symptomatological, neuropsychological, and functional outcome domains in schizophrenia: a prospective study in a real-world setting. Schizophr Res 133(1–3):223–231, 2011 21907544
Volavka J, Van Dorn RA, Citrome L, et al: Hostility in schizophrenia: an integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. Eur Psychiatry 31:13–19, 2016 26657597
Vraylar (cariprazine) [prescribing information]. Madison, NJ, Allergan USA, May 2019
Vuk A, Baretic M, Osvatic MM, et al: Treatment of diabetic ketoacidosis associated with antipsychotic medication: literature review. J Clin Psychopharmacol 37(5):584–589, 2017 28816925
Waddell L, Taylor M: A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol 22(3):238–243, 2008 18541624
Waddell L, Taylor M: Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl 52:S43–S50, 2009 19880916
Wade M, Tai S, Awenat Y, Haddock G: A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis. Clin Psychol Rev 51:75–95, 2017 27838461
Wagner E, Löhrs L, Siskind D, et al: Clozapine augmentation strategies: a systematic meta-review of available evidence: treatment options for clozapine resistance. J Psychopharmacol 33(4):423–435, 2019a
Wagner E, Wobrock T, Kunze B, et al: Efficacy of high-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with treatment-resistant negative symptoms treated with clozapine. Schizophr Res 208:370–376, 2019b
Walburn J, Gray R, Gournay K, et al: Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179:300–307, 2001 11581109
Walker ER, McGee RE, Druss BG: Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72(4):334–341, 2015 25671328
Waln O, Jankovic J: Paroxysmal movement disorders. Neurol Clin 33(1):137–152, 2015 25432727
Wampold BE: How important are the common factors in psychotherapy? An update. World Psychiatry 14(3):270–277, 2015 26407772
Wang G, Zheng W, Li XB, et al: ECT augmentation of clozapine for clozapine-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Psychiatr Res 105:23–32, 2018 30144667
Wang K, Varma DS, Prosperi M: A systematic review of the effectiveness of mobile apps for monitoring and management of mental health symptoms or disorders. J Psychiatr Res 107:73–78, 2018 30347316
Wang PS, Walker AM, Tsuang MT, et al: Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 59(12):1147–1154, 2002 12470131
Ward M, Druss B: The epidemiology of diabetes in psychotic disorders. Lancet Psychiatry 2(5):431–451, 2015 26360287
Warnez S, Alessi-Severini S: Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 14:102, 2014 24708834
Watkins K, Horvitz-Lennon M, Caldarone LB, et al: Developing medical record-based performance indicators to measure the quality of mental healthcare. J Healthc Qual 33(1):49–66, quiz 66–67, 2011
Watkins KE, Farmer CM, De Vries D, Hepner KA: The Affordable Care Act: an opportunity for improving care for substance use disorders? Psychiatr Serv 66(3):310–312, 2015
Watkins KE, Smith B, Akincigil A, et al: The quality of medication treatment for mental disorders in the Department of Veterans Affairs and in private-sector plans. Psychiatr Serv 67(4):391–396, 2016
Way BB, Miraglia R, Sawyer DA, Beer RJ: Factors related to suicide in New York State prisons. Int J Law Psychiatry 28(3):207–221, 2005 15950281
Weaver J, Kawsky J, Corboy A: Antipsychotic use and fracture risk: an evaluation of incidence at a Veterans Affairs medical center. Ment Health Clin 9(1):6–11, 2019 30627497
Weibell MA, Hegelstad WTV, Auestad B, et al: The effect of substance use on 10-year outcome in first-episode psychosis. Schizophr Bull 43(4):843–851, 2017 28199703
Weiden PJ, Roma RS, Velligan DI, et al: The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry 76(6):684–690, 2015 25939027
Wenzlow AT, Ireys HT, Mann B, et al: Effects of a discharge planning program on Medicaid coverage of state prisoners with serious mental illness. Psychiatr Serv 62(1):73–78, 2011 21209303
West JC, Marcus SC, Wilk J, et al: Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 34(5):995–1001, 2008 18093962
Whicher CA, Price HC, Holt RIG: Mechanisms in endocrinology: antipsychotic medication and type 2 diabetes and impaired glucose regulation. Eur J Endocrinol 178(6):R245–R258, 2018 29559497
Whirl-Carrillo M, McDonagh EM, Hebert JM, et al: Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92(4):414–417, 2012 22992668
WHOQOL Group: Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 28(3):551–558, 1998
Wilder CM, Elbogen EB, Moser LL, et al: Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directives. Psychiatr Serv 61(4):380–385, 2010 20360277
Wilper AP, Woolhandler S, Boyd JW, et al: The health and health care of US prisoners: results of a nationwide survey. Am J Public Health 99(4):666–672, 2009 19150898
Wimberley T, MacCabe JH, Laursen TM, et al: Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 174(10):990–998, 2017 28750580
Winston A: Supportive psychotherapy, in The American Psychiatric Publishing Textbook of Psychiatry, 6th Edition. Edited by Hales RE, Yudofsky SC, Roberts LW. Washington, DC, American Psychiatric Publishing, 2014, pp 1161–1186
Winston A, Rosenthal RN, Pinsker H: Learning Supportive Psychotherapy: An Illustrated Guide. Washington, DC, American Psychiatric Publishing, 2012, p 211
Witt K, van Dorn R, Fazel S: Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. PLoS One 8(2):e55942, 2013 23418482
Witt K, Hawton K, Fazel S: The relationship between suicide and violence in schizophrenia: analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) dataset. Schizophr Res 154(1–3):61–67, 2014 24581550
Witt K, Lichtenstein P, Fazel S: Improving risk assessment in schizophrenia: epidemiological investigation of criminal history factors. Br J Psychiatry 206(5):424–430, 2015
Wittenauer Welsh J, Janjua AU, Garlow SJ, et al: Use of expert consultation in a complex case of neuroleptic malignant syndrome requiring electroconvulsive therapy. J Psychiatr Pract 22(6):484489, 2016 27824784
Wium-Andersen MK, Ørsted DD, Nordestgaard BG: Tobacco smoking is causally associated with antipsychotic medication use and schizophrenia, but not with antidepressant medication use or depression. Int J Epidemiol 44(2):566–577, 2015
Wojcik JD, Falk WE, Fink JS, et al: A review of 32 cases of tardive dystonia. Am J Psychiatry 148(8):1055–1059, 1991 1677236
Wong J, Delva N: Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 52(7):457–463, 2007 17688010
Wong Z, Öngür D, Cohen B, et al: Command hallucinations and clinical characteristics of suicidality in patients with psychotic spectrum disorders. Compr Psychiatry 54(6):611–617, 2013 23375263
Wood L, Burke E, Morrison A: Individual cognitive behavioural therapy for psychosis (CBTp): a systematic review of qualitative literature. Behav Cogn Psychother 43(3):285–297, 2015 24308817
Woods SW, Morgenstern H, Saksa JR, et al: Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 71(4):463–474, 2010 20156410
Woosley RL, Heise CW, Gallo T: QTdrugs List. Oro Valley, AZ, AZCERT, March 29, 2009. Available at: www.crediblemeds.org. Accessed April 23, 2019.
Woosley RL, Romero K, Heise CW, et al: Adverse Drug Event Causality Analysis (ADECA): a process for evaluating evidence and assigning drugs to risk categories for sudden death. Drug Saf 40(6):465–474, 2017
Wright JH, Turkington D, Kingdon DG, Basco MR: Cognitive-Behavior Therapy for Severe Mental Illness: An Illustrated Guide. Washington, DC, American Psychiatric Publishing, 2009
Wykes T, Steel C, Everitt B, Tarrier N: Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 34(3):523–537, 2008 17962231
Wykes T, Huddy V, Cellard C, et al: A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 168(5):472–485, 2011 21406461
Xenazine (tetrabenazine) tablets [prescribing information]. Deerfield, IL, Lundbeck, September 2018
Xia J, Merinder LB, Belgamwar MR: Psychoeducation for schizophrenia (update). Cochrane Database Syst Rev (6):CD002831, 2011 12076455
Yan H, Chen JD, Zheng XY: Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia. Psychopharmacology (Berl) 229(1):1–7, 2013 23832387
Yates K, Lång U, Cederlöf M, et al: Association of psychotic experiences with subsequent risk of suicidal ideation, suicide attempts, and suicide deaths: a systematic review and meta-analysis of longitudinal population studies. JAMA Psychiatry 76(2):180–189, 2019
Yeo V, Dowsey M, Alguera-Lara V, et al: Antipsychotic choice: understanding shared decision-making among doctors and patients. J Ment Health Jun 26:1–8, 2019 31240989 Epub ahead of print
Yoon HW, Lee JS, Park SJ, et al: Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study. Clin Neuropharmacol 39(6):288–294, 2016 27438182
Zanger UM, Schwab M: Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138(1):103–141, 2013 23333322
Zhang JP, Gallego JA, Robinson DG, et al: Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 16(6):1205–1218, 2013 23199972
Zhang Y, Liu Y, Su Y, et al: The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry 17(1):373, 2017 29162032
Zheng W, Li XB, Tang YL, et al: Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 35(5):499–509, 2015 26280837
Zheng W, Cao XL, Ungvari GS, et al: Electroconvulsive therapy added to non-clozapine antipsychotic medication for treatment resistant schizophrenia: meta-analysis of randomized controlled trials. PLoS One 11(6):e0156510, 2016 27285996
Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance, part I. Clin Pharmacokinet 48(11):689–723, 2009 19817501
Zhu Y, Krause M, Huhn M, et al: Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 4(9):694–705, 2017 28736102
Zhuo C, Xu Y, Liu S, et al: Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: a systematic review and network meta-analysis. Front Pharmacol 9:1393, 2018 30546312
Zimmer M, Duncan AV, Laitano D, et al: A twelve-week randomized controlled study of the cognitive-behavioral integrated psychological therapy program: positive effect on the social functioning of schizophrenic patients. Braz J Psychiatry 29(2):140–147, 2007 17650536
Zimmerman M, Chelminski I, Young D, Dalrymple K: Using outcome measures to promote better outcomes. Clinical Neuropsychiatry 8:28–36, 2011
Zou H, Li Z, Nolan MT, et al: Self-management education interventions for persons with schizophrenia: a meta-analysis. Int J Ment Health Nurs 22(3):256–271, 2013 22882803
Zubek JP, Bayer L, Shephard JM: Relative effects of prolonged social isolation and confinement: behavioral and EEG changes. J Abnorm Psychol 74(5):625–631, 1969
Zyprexa (olanzapine) [prescribing information]. Indianapolis, IN, Lilly USA, March 2018a
Zyprexa (olanzapine) [product monograph]. Toronto, ON, Canada, Eli Lilly Canada, April 2018b
Zyprexa Relprevv (olanzapine) [prescribing information]. Indianapolis, IN, Eli Lilly, March 2018
Information & Authors
Information
Published In
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia
September 2020
©American Psychiatric Association Publishing
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).